Research
Plain-language summaries of published studies, grouped by research area. Each entry names the study type and the species studied, and links to the original paper. Summaries are written in-house from the abstracts and describe reported findings only. Select any paper to open its full details.
823 papers
-
Review of how NNMT inhibitors have been developed and what hurdles remain before testing in people; draws on cell and animal work.
Trends Pharmacol Sci, 2026 PubMed
-
In a mouse model of peripheral artery disease, NNMT inhibition was reported to improve strength and power in ischemic limbs without changing muscle size.
Physiol Rep, 2025 PubMed
-
Cell-culture study in which NNMT inhibitors were reported to lower viability and trigger cell-death pathways in osteosarcoma and mesothelioma cells.
Biomolecules, 2025 PubMed
-
Mouse and patient-tissue study linking NNMT in tumor-associated fibroblasts to tumor growth and poorer response to immunotherapy.
J Immunother Cancer, 2024 PubMed
-
Aged-mouse study reporting that an NNMT inhibitor improved measures of muscle function, both alone and alongside exercise training.
Sci Rep, 2024 PubMed
-
In diet-induced obese mice, researchers reported that blocking the enzyme NNMT reduced weight and fat gain and lessened fatty-liver changes.
Diabetes Obes Metab, 2024 PubMed
-
In diet-induced obese mice, researchers reported that a lower-calorie diet plus NNMT inhibition produced a distinct gut-microbiome profile.
Sci Rep, 2022 PubMed
-
In obese mice moved to a lower-calorie diet, adding an NNMT inhibitor was reported to further normalize body composition and change fat-tissue metabolites.
Sci Rep, 2021 PubMed
-
In aged mice with muscle injury, an NNMT inhibitor was reported to activate muscle stem cells and improve regeneration; cultured myoblasts showed similar changes.
Biochem Pharmacol, 2019 PubMed
-
Mouse and fat-cell study in which small-molecule NNMT inhibitors were reported to reduce body weight and white fat in high-fat-fed obese mice.
Biochem Pharmacol, 2018 PubMed
-
Mouse study comparing nanoparticle and conjugate delivery of fat-targeting peptides; nanoparticle delivery was reported to work better in obese fat.
J Control Release, 2013 PubMed
-
Published comment arguing that the adipotide monkey results may reflect a direct effect on fat tissue rather than on its blood vessels.
Sci Transl Med, 2012 PubMed
-
In high-fat-fed mice, a fat-vessel-targeting peptide was reported to improve glucose tolerance before major weight changes occurred.
Diabetes, 2012 PubMed
-
In obese monkeys of three species, adipotide was reported to cause weight loss and better insulin sensitivity, with reversible kidney-tubule changes.
Sci Transl Med, 2011 PubMed
-
Mouse study in which a peptide targeting the blood vessels of white fat was reported to shrink fat tissue and reverse obesity.
Nat Med, 2004 PubMed
-
Review of approved and unapproved peptides discussed for musculoskeletal injury, summarizing the limited human evidence.
Sports Med, 2026 PubMed
-
In a rabbit osteoarthritis model, intra-articular AOD9604 was reported to improve cartilage repair, more so when combined with hyaluronic acid.
Ann Clin Lab Sci, 2015 PubMed
-
Obese-mouse study reporting that both growth hormone and its fragment AOD9604 reduced weight gain and increased fat burning.
Int J Obes Relat Metab Disord, 2001 PubMed
-
Mouse study (including beta-3 receptor knockout mice) examining how growth hormone and AOD9604 affect fat metabolism.
Endocrinology, 2001 PubMed
-
Rat study reporting that, unlike intact growth hormone, long-term AOD9604 did not impair insulin sensitivity.
Horm Res, 2000 PubMed
-
Meta-analysis of human trials reporting weight loss and cardiometabolic changes with cagrilintide and CagriSema, with acceptable tolerability.
J Diabetes Metab Disord, 2026 PubMed
-
Randomized human trial in type 2 diabetes comparing cagrilintide-semaglutide with each drug alone; the combination lowered HbA1c more than semaglutide.
Lancet Diabetes Endocrinol, 2026 PubMed
-
Randomized human trial in adults with obesity and type 2 diabetes reporting lower body weight with weekly cagrilintide-semaglutide than placebo.
N Engl J Med, 2025 PubMed
-
Large randomized human trial reporting greater body-weight reduction with cagrilintide plus semaglutide than with placebo in adults with overweight or obesity.
N Engl J Med, 2025 PubMed
-
Meta-analysis of human trials comparing cagrilintide, alone and with semaglutide, against other weight-management drugs.
Indian J Endocrinol Metab, 2024 PubMed
-
Randomized human trial in type 2 diabetes reporting improved glucose control, including continuous glucose monitoring measures, with CagriSema.
Lancet, 2023 PubMed
-
Randomized dose-finding human trial reporting body-weight reductions with once-weekly cagrilintide, which was generally well tolerated.
Lancet, 2021 PubMed
-
Human observational study reporting similar gastrointestinal safety profiles for dulaglutide, semaglutide and tirzepatide in type 2 diabetes.
Ann Intern Med, 2026 PubMed
-
Randomized human cardiovascular outcomes trial in type 2 diabetes reporting tirzepatide was noninferior to dulaglutide.
N Engl J Med, 2025 PubMed
-
Randomized human trial in youths with type 2 diabetes reporting better glucose control with weekly dulaglutide than placebo over 26 weeks.
N Engl J Med, 2022 PubMed
-
Exploratory analysis of a human trial suggesting long-term dulaglutide was linked to less cognitive decline in type 2 diabetes.
Lancet Neurol, 2020 PubMed
-
Large randomized human trial (REWIND) reporting fewer major cardiovascular events with dulaglutide in type 2 diabetes.
Lancet, 2019 PubMed
-
Randomized human trial reporting better glucose control when dulaglutide was added to SGLT2 inhibitors in type 2 diabetes.
Lancet Diabetes Endocrinol, 2018 PubMed
-
Randomized human trial in type 2 diabetes with chronic kidney disease; dulaglutide gave glucose control similar to insulin glargine.
Lancet Diabetes Endocrinol, 2018 PubMed
-
Randomized human trial (SUSTAIN 7) reporting that semaglutide lowered HbA1c and body weight more than dulaglutide.
Lancet Diabetes Endocrinol, 2018 PubMed
-
Early-phase human study reporting that weekly eloralintide was well tolerated and produced weight loss.
Diabetes Obes Metab, 2026 PubMed
-
Meta-analysis of human trials of newer amylin-based therapies reporting weight loss alongside more gastrointestinal side effects.
Endocrinol Diabetes Metab, 2026 PubMed
-
Report tracing eloralintide from discovery through early human studies, highlighting its selectivity for one amylin receptor.
Mol Metab, 2025 PubMed
-
48-week randomized human trial reporting dose-related body-weight reductions with eloralintide, which was generally well tolerated.
Lancet, 2025 PubMed
-
Review of peptide drugs used as doping agents in sport, describing them as experimental with poorly defined long-term risks.
J Sports Med Phys Fitness, 2026 PubMed
-
Obese-mouse study reporting less weight gain and fat mass with the hGH 177-191 fragment.
Biochem Mol Biol Int, 1994 PubMed
-
Rat study reporting that the hGH 177-191 fragment reduced fat formation without increasing fat breakdown.
Biochem Mol Biol Int, 1993 PubMed
-
Rat fat-cell study reporting that an hGH fragment affected glucose transport more potently than intact growth hormone.
Biochem Mol Biol Int, 1993 PubMed
-
Rat study testing shortened hGH fragments, finding most lost their insulin-opposing activity.
Acta Endocrinol (Copenh), 1982 PubMed
-
Rat study reporting that some C-terminal hGH fragments reduced insulin sensitivity and raised blood glucose.
Am J Physiol, 1978 PubMed
-
Human case report of severe low blood sugar from hidden insulin use in a bodybuilder.
J Emerg Med, 2019 PubMed
-
Endocrine Society scientific statement reviewing the adverse health effects of performance-enhancing drugs, including insulin.
Endocr Rev, 2014 PubMed
-
Human case report and literature review of a suicide attempt by massive insulin injection, with full recovery after careful glucose management.
J Med Assoc Thai, 2008 PubMed
-
Review of GH, IGF-I and insulin misuse in sport and how such use can be detected.
Br J Pharmacol, 2008 PubMed
-
Human study reporting that muscle protein metabolism becomes less responsive to insulin with aging.
FASEB J, 2006 PubMed
-
Human study reporting that insulin infusion reduced muscle protein breakdown, part of insulin's anabolic effect on muscle.
Am J Physiol Endocrinol Metab, 2006 PubMed
-
Human case report of dangerous hypoglycemia after insulin used as an anabolic in bodybuilding.
Anasthesiol Intensivmed Notfallmed Schmerzther, 1998 PubMed
-
Review of how insulin affects protein metabolism, including muscle protein deposition when amino acids are available.
Baillieres Clin Endocrinol Metab, 1993 PubMed
-
Umbrella meta-analysis of human trials reporting that L-carnitine supplementation modestly reduced weight, BMI and waist circumference.
Int J Vitam Nutr Res, 2025 PubMed
-
Randomized human trial finding no added benefit of L-carnitine on weight gain in children with severe acute malnutrition.
J Nutr, 2024 PubMed
-
Meta-analysis reporting small reductions in blood lipids and glucose with L-carnitine in type 2 diabetes, with high variability.
Clin Ther, 2024 PubMed
-
Meta-analysis reporting that L-carnitine did not change body measures in hemodialysis patients.
Pharmacol Res, 2020 PubMed
-
Systematic review and meta-analysis reporting a modest weight, BMI and fat-mass reduction with L-carnitine, especially in people with overweight or obesity.
Clin Nutr ESPEN, 2020 PubMed
-
Systematic review of benefits and risks of L-carnitine, noting raised blood TMAO levels with prolonged use.
J Int Soc Sports Nutr, 2020 PubMed
-
Systematic review and meta-analysis of human trials examining L-carnitine and weight loss in adults.
Obes Rev, 2016 PubMed
-
Risk-assessment review concluding strong safety evidence for L-carnitine up to about 2000 mg/day for long-term use.
Regul Toxicol Pharmacol, 2006 PubMed
-
Human case report of acute respiratory distress possibly following cosmetic fat-dissolving injection, urging caution.
Am J Case Rep, 2026 PubMed
-
Review of mycobacterial skin and soft-tissue infections after injection lipolysis, stressing aseptic technique.
J Cosmet Dermatol, 2023 PubMed
-
Review of cosmetic mesotherapy weighing the scientific evidence against marketing claims.
Aesthetic Plast Surg, 2008 PubMed
-
Systematic review reporting higher homocysteine but no clear vitamin B12 difference in children and adolescents with obesity.
Front Public Health, 2025 PubMed
-
Human observational study reporting lower vitamin B12 levels and more deficiency in women with obesity.
Niger J Clin Pract, 2017 PubMed
-
Review of plant-based foods as sources of lipotropic nutrients (such as choline and methionine) in human nutrition.
Crit Rev Food Sci Nutr, 2013 PubMed
-
Narrative review of weight-management dietary supplements, noting limited data on safety and metabolic benefits.
Nutrients, 2022 PubMed
-
Randomized human trial reporting favorable body-composition changes after four weeks of a natural dietary compound.
Adv Ther, 1998 PubMed
-
Randomized human trial reporting greater BMI reduction with liraglutide plus lifestyle therapy in children aged 6 to under 12 with obesity.
N Engl J Med, 2025 PubMed
-
Randomized human trial reporting greater weight loss with weekly semaglutide than daily liraglutide in adults with overweight or obesity.
JAMA, 2022 PubMed
-
Randomized human trial reporting that combining exercise and liraglutide maintained weight loss better than either alone.
N Engl J Med, 2021 PubMed
-
Randomized human trial reporting that liraglutide plus lifestyle therapy lowered BMI more than placebo in adolescents with obesity.
N Engl J Med, 2020 PubMed
-
Randomized human trial reporting improved glucose control with liraglutide in children and adolescents with type 2 diabetes.
N Engl J Med, 2019 PubMed
-
Randomized human trial reporting that three years of liraglutide reduced diabetes risk and supported weight loss versus placebo.
Lancet, 2017 PubMed
-
Randomized human trial reporting that liraglutide 3.0 mg reduced obstructive sleep apnea severity more than placebo in people with obesity.
Int J Obes (Lond), 2016 PubMed
-
Randomized human trial (LEAN) reporting that liraglutide was well tolerated and led to resolution of non-alcoholic steatohepatitis in some patients.
Lancet, 2016 PubMed
-
Randomized human trial in Chinese adults with type 2 diabetes reporting HbA1c and weight reductions with mazdutide versus dulaglutide.
Nature, 2026 PubMed
-
Randomized human trial reporting that mazdutide lowered HbA1c and weight versus placebo in Chinese adults with type 2 diabetes, with typical GLP-1 side effects.
Nature, 2026 PubMed
-
Randomized human trial in Chinese adults with obesity or overweight reporting clinically relevant weight loss with once-weekly mazdutide.
N Engl J Med, 2025 PubMed
-
Randomized double-blind human trial reporting meaningful HbA1c and weight reductions with mazdutide in Chinese patients with type 2 diabetes.
Diabetes Care, 2024 PubMed
-
Systematic review and meta-analysis of human trials reporting that mazdutide was effective for weight loss in diabetic and non-diabetic patients.
Front Endocrinol (Lausanne), 2024 PubMed
-
Phase 2 randomized human trial reporting that mazdutide was well tolerated in Chinese adults with overweight or obesity.
Nat Commun, 2023 PubMed
-
Human study of higher-dose mazdutide (a GLP-1/glucagon dual agonist) reporting good tolerability and promising 12-week weight results.
EClinicalMedicine, 2022 PubMed
-
Randomized human trial reporting that retatrutide, a triple GIP/GLP-1/glucagon agonist, improved glucose control and body weight in type 2 diabetes.
Lancet, 2026 PubMed
-
Meta-analysis of human trials reporting significant weight and metabolic improvements with retatrutide and an acceptable safety profile.
Proc (Bayl Univ Med Cent), 2025 PubMed
-
Systematic review and meta-analysis reporting significant weight loss and metabolic improvement with once-weekly retatrutide.
Metabol Open, 2024 PubMed
-
Randomized human trial reporting reduced liver fat with retatrutide in metabolic-associated fatty liver disease, linked to weight and fat loss.
Nat Med, 2024 PubMed
-
Randomized human trial reporting clinically meaningful glucose control and large weight reductions with retatrutide in type 2 diabetes.
Lancet, 2023 PubMed
-
Phase 2 randomized human trial reporting substantial body-weight reductions over 48 weeks with retatrutide in adults with obesity.
N Engl J Med, 2023 PubMed
-
Early human study of the triple agonist LY3437943 (retatrutide) reporting once-weekly dosing support and persistent weight reduction after a single dose.
Cell Metab, 2022 PubMed
-
Human observational study suggesting an association between semaglutide and a rare optic-nerve condition (NAION), needing confirmation.
JAMA Ophthalmol, 2024 PubMed
-
Randomized human trial (SELECT) reporting fewer cardiovascular events with weekly semaglutide in people with overweight/obesity and cardiovascular disease but no diabetes.
N Engl J Med, 2023 PubMed
-
Systematic review reporting about 12% weight reduction with subcutaneous semaglutide in obesity without type 2 diabetes.
J ASEAN Fed Endocr Soc, 2022 PubMed
-
Randomized human trial reporting greater BMI reduction with weekly semaglutide plus lifestyle intervention in adolescents with obesity.
N Engl J Med, 2022 PubMed
-
Extension of the STEP 1 trial reporting that participants regained about two-thirds of lost weight a year after stopping semaglutide.
Diabetes Obes Metab, 2022 PubMed
-
Randomized human trial reporting that continued weekly semaglutide maintained weight loss, while switching to placebo led to regain.
JAMA, 2021 PubMed
-
Randomized human trial (STEP 1) reporting sustained, clinically meaningful weight loss with weekly semaglutide plus lifestyle intervention.
N Engl J Med, 2021 PubMed
-
Randomized human trial (STEP 2) reporting superior weight loss with weekly semaglutide 2.4 mg in adults with overweight/obesity and type 2 diabetes.
Lancet, 2021 PubMed
-
Human observational study reporting that setmelanotide improved fatty liver and kidney filtration in Bardet-Biedl syndrome, independent of weight.
J Clin Endocrinol Metab, 2026 PubMed
-
Human case series reporting benefit from setmelanotide in young patients with severe obesity after craniopharyngioma.
J Endocrinol Invest, 2026 PubMed
-
Randomized human trial reporting greater BMI and hunger reductions with setmelanotide than placebo in acquired hypothalamic obesity.
N Engl J Med, 2026 PubMed
-
52-week human analysis providing further evidence that setmelanotide improves weight outcomes in Bardet-Biedl syndrome.
Obesity (Silver Spring), 2026 PubMed
-
Real-world human study confirming long-term benefit and safety of setmelanotide in monogenic or syndromic obesity.
Obesity (Silver Spring), 2025 PubMed
-
Human trial (VENTURE) reporting benefit of setmelanotide in children aged 2-5 with rare MC4R-pathway obesity.
Lancet Diabetes Endocrinol, 2025 PubMed
-
Phase 2 open-label human study supporting setmelanotide as an effective treatment for hypothalamic obesity.
Lancet Diabetes Endocrinol, 2024 PubMed
-
Randomized human trial reporting weight reductions with setmelanotide in Bardet-Biedl syndrome, with inconclusive results in Alström syndrome.
Lancet Diabetes Endocrinol, 2022 PubMed
-
Human study reporting weight and hunger reductions with setmelanotide in severe obesity from POMC or leptin-receptor deficiency.
Lancet Diabetes Endocrinol, 2020 PubMed
-
Human study reporting weight loss with setmelanotide in people with MC4R deficiency, with calls for further study.
Mol Metab, 2017 PubMed
-
Meta-analysis of human trials of dual GLP-1/glucagon agonists reporting meaningful weight loss and metabolic improvement with acceptable short-term safety.
Diabetes Obes Metab, 2026 PubMed
-
Randomized human trial reporting reduced liver fat (MRI-PDFF) with survodutide in obesity with at-risk fatty liver disease.
Nat Med, 2026 PubMed
-
Randomized human trial reporting greater weight loss with weekly survodutide than placebo in adults with obesity without diabetes.
N Engl J Med, 2026 PubMed
-
Randomized human trial reporting significant weight reduction with survodutide in adults with obesity and type 2 diabetes.
N Engl J Med, 2026 PubMed
-
Phase 2 randomized human trial reporting that survodutide improved MASH without worsening fibrosis.
N Engl J Med, 2024 PubMed
-
Randomized human trial reporting HbA1c and body-weight reductions with survodutide over 16 weeks in type 2 diabetes, with dose-related GI side effects.
Diabetologia, 2024 PubMed
-
Meta-analysis of human trials reporting that survodutide reduced weight, BMI and waist circumference, more so with longer treatment.
Diabetol Metab Syndr, 2024 PubMed
-
Human study reporting that survodutide was generally tolerable in people with cirrhosis without needing dose adjustment.
J Hepatol, 2024 PubMed
-
Randomized double-blind human trial reporting dose-dependent weight reduction with survodutide in obesity.
Lancet Diabetes Endocrinol, 2024 PubMed
-
Mouse study describing the discovery and preclinical pharmacology of BI 456906 (survodutide), a GCGR/GLP-1R dual agonist with anti-obesity activity.
Mol Metab, 2022 PubMed
-
Rat study reporting that tesofensine raised heart rate and blood pressure via sympathetic activity, which antihypertensive co-treatment prevented.
Obesity (Silver Spring), 2013 PubMed
-
Published expression of concern regarding a tesofensine weight-loss trial.
Lancet, 2013 PubMed
-
Letter reporting concerns about under-reported adverse effects of tesofensine.
Lancet, 2013 PubMed
-
Randomized human study reporting that tesofensine enhanced satiety, which may explain early weight loss.
Obesity (Silver Spring), 2012 PubMed
-
Randomized human study reporting that the abuse potential of tesofensine was no greater than bupropion or atomoxetine.
Clin Pharmacol Ther, 2010 PubMed
-
Randomized human trial reporting that tesofensine produced notable weight loss in obese patients, warranting confirmation.
Lancet, 2008 PubMed
-
Randomized human trial reporting modest motor improvements with tesofensine in advanced Parkinson's disease.
Arch Neurol, 2008 PubMed
-
Meta-analysis reporting that tesofensine produced about 4% placebo-subtracted weight loss in Parkinson's or Alzheimer's patients.
Obesity (Silver Spring), 2008 PubMed
-
Randomized human trial reporting greater weight loss with tirzepatide than semaglutide in adults with obesity without diabetes.
N Engl J Med, 2025 PubMed
-
Randomized human trial reporting lower risk of cardiovascular death or worsening heart failure with tirzepatide in heart failure with preserved ejection fraction and obesity.
N Engl J Med, 2025 PubMed
-
Three-year randomized human trial reporting substantial weight loss and markedly lower diabetes onset with tirzepatide in obesity and prediabetes.
N Engl J Med, 2025 PubMed
-
Randomized human trial reporting that continued tirzepatide maintained weight loss while withdrawal led to substantial regain.
JAMA, 2024 PubMed
-
Randomized human trial reporting that tirzepatide reduced apnea-hypopnea index and body weight in obstructive sleep apnea with obesity.
N Engl J Med, 2024 PubMed
-
Pre-specified meta-analysis of human trials assessing cardiovascular event risk with tirzepatide, finding no adverse signal.
Nat Med, 2022 PubMed
-
72-week randomized human trial reporting substantial, sustained weight reduction with once-weekly tirzepatide in obesity.
N Engl J Med, 2022 PubMed
-
Randomized human trial reporting that tirzepatide lowered HbA1c more than semaglutide in type 2 diabetes.
N Engl J Med, 2021 PubMed
-
Human study in healthy older adults reporting that nightly GHRH(1-29) injections changed muscle strength and its link to muscle energy measures.
Metabolism, 1997 PubMed
-
Human study in children with idiopathic short stature reporting sustained growth during twice-daily GHRH(1-29) treatment.
Clin Endocrinol (Oxf), 1994 PubMed
-
Enzyme study measuring how quickly DPP-IV breaks down GRF and its analogs, depending on their chemical structure.
Biochim Biophys Acta, 1992 PubMed
-
Lab study in pig plasma showing that structural changes such as cyclization made GRF analog peptides more stable.
Horm Metab Res, 1991 PubMed
-
One-year human study in short, slowly growing children reporting that continuous GHRH(1-29) promoted growth in some of them.
Clin Endocrinol (Oxf), 1990 PubMed
-
Review of performance-enhancing peptides acting on the GH-IGF1 axis, summarizing pharmacology and reported adverse effects.
Front Endocrinol (Lausanne), 2026 PubMed
-
Human study of CJC-1295 that identified serum proteins changing with activation of the GH/IGF-1 axis.
Growth Horm IGF Res, 2009 PubMed
-
Mouse study in GHRH-knockout mice reporting that once-daily CJC-1295 maintained normal growth and body composition.
Am J Physiol Endocrinol Metab, 2006 PubMed
-
Randomized human trial in healthy adults reporting sustained, dose-related rises in GH and IGF-I after CJC-1295, with acceptable safety.
J Clin Endocrinol Metab, 2006 PubMed
-
Human study reporting that CJC-1295 raised average GH and IGF-I while natural GH pulses were preserved.
J Clin Endocrinol Metab, 2006 PubMed
-
Rat and lab study showing that CJC-1295 binds albumin in the blood and still activates the GRF receptor.
Endocrinology, 2005 PubMed
-
Review of growth hormone secretagogues, summarizing human safety data and gaps on long-term effects.
Sex Med Rev, 2018 PubMed
-
Randomized human study in men showing that age, sex steroids, belly fat and the type of secretagogue each influenced cortisol pulses.
Eur J Endocrinol, 2010 PubMed
-
Human study reporting that a GHRP-2 stimulation test reproducibly identified severe adult GH deficiency.
Eur J Endocrinol, 2007 PubMed
-
Rat and dog study describing the pharmacology of GHRP-2 (KP-102), including GH release and growth effects in rats.
Arzneimittelforschung, 2004 PubMed
-
Randomized human study in prolonged critical illness reporting that combined GHRP-2, TRH and GnRH reactivated several pituitary hormone axes in men.
Clin Endocrinol (Oxf), 2002 PubMed
-
Phase I human study describing how GHRP-2 is cleared from the blood and the resulting rise in GH.
J Clin Endocrinol Metab, 1998 PubMed
-
Human study in children with short stature reporting that intranasal GHRP-2 was well tolerated and raised GH-binding protein levels.
J Endocrinol, 1997 PubMed
-
Rat study reporting that GHRP-6 protected the heart from doxorubicin damage by supporting antioxidant defenses and mitochondria.
Front Pharmacol, 2024 PubMed
-
Rat and rabbit wound study reporting faster healing and better scar appearance with GHRP-6, but no effect on established scars.
Plast Surg Int, 2016 PubMed
-
Pharmacokinetic study in nine healthy men describing how GHRP-6 blood levels scaled with the amount given.
Eur J Pharm Sci, 2013 PubMed
-
Human study reporting that a combined GHRH/GHRP-6 test was a reliable diagnostic test for adult GH deficiency.
Lancet, 2000 PubMed
-
Human study in children with short stature measuring GH release after GHRP-6 taken by mouth.
Eur J Endocrinol, 1995 PubMed
-
Randomized human study reporting that GHRP-6 increased stage 2 sleep and GH, ACTH and cortisol release.
Neuroendocrinology, 1995 PubMed
-
Mouse study reporting that hexarelin reduced abdominal aortic aneurysm formation by limiting vessel-cell changes and inflammation.
Microvasc Res, 2022 PubMed
-
Mouse atherosclerosis study (ApoE knockout) reporting that hexarelin slowed plaque progression and changed blood lipids.
Peptides, 2019 PubMed
-
Review of cardiovascular research on hexarelin in animal and human studies.
J Geriatr Cardiol, 2014 PubMed
-
Human study in coronary bypass patients reporting improved cardiac performance measures right after hexarelin.
Eur J Pharmacol, 2002 PubMed
-
Randomized human study reporting that two or three daily hexarelin injections raised 24-hour GH secretion equally.
Eur J Endocrinol, 2002 PubMed
-
Human study reporting no over-stimulation of the adrenal axis or prolactin during chronic hexarelin.
Clin Endocrinol (Oxf), 1999 PubMed
-
Long-term human study reporting minimal lasting impact of a hexarelin schedule on the GH-IGF-I axis.
J Clin Endocrinol Metab, 1998 PubMed
-
Human study in short children reporting faster growth and higher GH/IGF-I with long-term intranasal hexarelin.
Clin Endocrinol (Oxf), 1995 PubMed
-
Meta-analysis of human trials of GH in osteoporosis, reporting possible bone effects and more adverse events.
Can J Aging, 2017 PubMed
-
Review of human safety data on adult GH replacement in severe GH deficiency, generally describing it as safe.
Growth Horm IGF Res, 2015 PubMed
-
Systematic review of GH treatment in adults with GH deficiency, recommending individualized assessment.
Clin Endocrinol (Oxf), 2014 PubMed
-
Cochrane review of human trials reporting faster height gain in children with chronic kidney disease given GH for a year.
Cochrane Database Syst Rev, 2012 PubMed
-
Systematic review concluding that claims of GH improving athletic performance are not supported by the human evidence.
Ann Intern Med, 2008 PubMed
-
Meta-analysis of human trials reporting improved exercise capacity with GH replacement in adults with GH deficiency.
J Clin Endocrinol Metab, 2008 PubMed
-
Systematic review of human trials of GH in healthy older adults, reporting small body-composition changes and frequent side effects.
Ann Intern Med, 2007 PubMed
-
Randomized human study in GH-deficient adults reporting reduced insulin sensitivity during short-term GH replacement.
Growth Horm IGF Res, 1999 PubMed
-
Rat cortical-injury model reporting that prenatal (1-3)IGF-1 was ineffective and had detrimental behavioral effects.
Brain Behav, 2026 PubMed
-
Human prostate-cell (BPH) study reporting that a vitamin D3 analog inhibited des(1-3)IGF-I-stimulated cell growth.
Mol Cell Endocrinol, 2002 PubMed
-
Mutant-p53 mouse study reporting that des(1-3)IGF-I overexpression accelerated mammary tumor development.
Oncogene, 2000 PubMed
-
Review of des(1-3)IGF-I, a truncated IGF-I form with greater potency and selective effects on gut tissue.
Int J Biochem Cell Biol, 1996 PubMed
-
Rat brain-injury study examining IGF-1, IGF-2 and des-IGF-1 on neuron loss and the role of IGF binding proteins.
Endocrinology, 1996 PubMed
-
Rat heart study reporting that IGF-I reduced heart-muscle cell death after ischemia-reperfusion.
Proc Natl Acad Sci U S A, 1995 PubMed
-
Rat study reporting improved nitrogen balance and food efficiency with IGF-I and des(1-3)IGF-I.
Miner Electrolyte Metab, 1992 PubMed
-
Rat gut-resection study reporting enhanced growth with IGF-I and the truncated des-(1-3)IGF-I analog.
Am J Physiol, 1991 PubMed
-
Rat diabetes study reporting increased weight gain, nitrogen retention and muscle protein synthesis with IGF peptides including des(1-3)IGF-I.
Biochem J, 1991 PubMed
-
Mouse study reporting that des(1-3)IGF-I was more potent than IGF-I, with some organ-weight increases at higher doses.
J Endocrinol, 1990 PubMed
-
Study in growth-restricted fetal sheep reporting that IGF-1 LR3 did not promote fetal growth.
Am J Physiol Endocrinol Metab, 2025 PubMed
-
Alzheimer's model mouse study reporting that intranasal LR3-IGF-1 remodeled amyloid plaques but did not preserve memory.
J Alzheimers Dis, 2025 PubMed
-
Fetal sheep study reporting that IGF-1 LR3 infusion blunted glucose-stimulated insulin secretion.
J Dev Orig Health Dis, 2023 PubMed
-
Study in artificially reared newborn pigs reporting increased growth with IGF-I and its analogs.
Br J Nutr, 2002 PubMed
-
Pig study reporting that IGF-I variants binding poorly to IGF binding proteins caused stronger and longer blood-glucose lowering.
J Endocrinol, 1997 PubMed
-
Pig study reporting that Long R3 IGF-I reduced growth and lowered plasma GH, IGF-I and binding proteins.
J Endocrinol, 1997 PubMed
-
Rat study reporting that infused LR3-IGF-I was more potent than IGF-I despite faster clearance, because it binds IGF binding proteins poorly.
J Endocrinol, 1996 PubMed
-
Guinea-pig study reporting that Long R3 IGF-I infusion stimulated organ growth while lowering circulating IGF-I.
J Endocrinol, 1995 PubMed
-
Rat small-bowel resection study reporting that LR3-IGF-I was more potent than IGF-I at improving weight gain and food conversion.
Growth Factors, 1994 PubMed
-
Rat study reporting that IGF-I and its variants countered steroid-induced tissue loss.
Biochem J, 1992 PubMed
-
Randomized human proof-of-concept study of ipamorelin for postoperative ileus; it was well tolerated but showed no significant benefit over placebo.
Int J Colorectal Dis, 2014 PubMed
-
Rodent postoperative-ileus model reporting that repeated ipamorelin dosing increased gut motility, food intake and weight.
J Pharmacol Exp Ther, 2009 PubMed
-
Rat study reporting that ipamorelin offset glucocorticoid-related losses in bone and muscle strength.
Growth Horm IGF Res, 2001 PubMed
-
Rat study reporting that ipamorelin induced longitudinal bone growth without changing pituitary GH content.
Growth Horm IGF Res, 1999 PubMed
-
Human pharmacokinetic-pharmacodynamic study modeling ipamorelin levels and GH responses across doses.
Pharm Res, 1999 PubMed
-
Rat and pig study describing ipamorelin as the first selective GH secretagogue of its kind.
Eur J Endocrinol, 1998 PubMed
-
Review of sermorelin's use in diagnosing and treating idiopathic GH deficiency in children.
BioDrugs, 1999 PubMed
-
Human study of a long-acting GHRH analog reporting anabolic effects, favoring men more than women.
J Clin Endocrinol Metab, 1997 PubMed
-
Human study reporting that once-daily sermorelin accelerated growth in GH-deficient children and was well tolerated.
J Clin Endocrinol Metab, 1996 PubMed
-
Randomized human study comparing GH and GHRH(1-29)-NH2 (sermorelin) for growth stimulation, with mild injection-site irritation in some.
Acta Paediatr Suppl, 1993 PubMed
-
Human study of continuous sermorelin infusion in children, linking growth response to baseline GH secretion.
Acta Paediatr Suppl, 1993 PubMed
-
Randomized human study comparing growth responses to GHRH(1-29)-NH2 (sermorelin) and growth hormone.
Acta Paediatr Suppl, 1993 PubMed
-
Meta-analysis reporting that tesamorelin improved body composition, liver fat and IGF-1 in HIV-associated lipodystrophy without serious side effects.
Obes Res Clin Pract, 2026 PubMed
-
Systematic review of tesamorelin in people living with HIV with lipodystrophy, noting limited long-term safety data.
J Int Assoc Provid AIDS Care, 2026 PubMed
-
Randomized human trial reporting that tesamorelin reduced waist size but did not significantly improve cognition in people with HIV and abdominal obesity.
J Infect Dis, 2025 PubMed
-
Randomized double-blind human trial suggesting tesamorelin might benefit non-alcoholic fatty liver disease in people with HIV, pending further study.
Lancet HIV, 2019 PubMed
-
Randomized human trial reporting favorable cognitive effects of 20 weeks of GHRH (tesamorelin) in adults with mild cognitive impairment and healthy older adults.
Arch Neurol, 2012 PubMed
-
Randomized human trial reporting that tesamorelin selectively reduced visceral fat in obese people with reduced GH.
J Clin Endocrinol Metab, 2012 PubMed
-
Randomized human trial reporting that tesamorelin reduced visceral fat by about 18% and eased body-image distress in HIV patients with central fat.
J Acquir Immune Defic Syndr, 2010 PubMed
-
Randomized human trial reporting that daily tesamorelin reduced visceral fat and improved lipids in HIV patients over 26 weeks.
N Engl J Med, 2007 PubMed
-
Critical review of rodent ischemia-reperfusion studies of BPC 157, concluding the evidence is hypothesis-generating rather than conclusive.
Int J Mol Sci, 2026 PubMed
-
Review arguing that BPC-157 lacks basic pharmaceutical data (stability, formulation, dose-response) needed before human trials.
Pharmaceutics, 2026 PubMed
-
Exploratory rat study reporting better tissue structure in healing Achilles tendons with BPC-157 or TB-500.
Jt Dis Relat Surg, 2026 PubMed
-
Lab study on human artery tissue reporting that BPC 157 relaxed blood vessels largely through nitric oxide from the vessel lining.
J Clin Med, 2026 PubMed
-
Review of peptides discussed in sports medicine, noting animal findings but no supporting human trials for recovery or performance claims.
Am J Sports Med, 2026 PubMed
-
Preprint analyzing online patient reports of BPC-157 use; reported side effects were uncommon but likely under-reported, including some psychiatric effects.
Preprints.org, 2026 Europe PMC
-
Systematic review of BPC-157 in orthopedic sports medicine, noting mostly animal data and possible risks from unregulated manufacturing.
HSS J, 2025 PubMed
-
Narrative review of BPC-157 and musculoskeletal healing that describes strong animal data, almost no human data, and calls it investigational.
Curr Rev Musculoskelet Med, 2025 PubMed
-
Two-person human pilot of intravenous BPC-157 that reported no adverse effects on the safety measures checked.
Altern Ther Health Med, 2025 PubMed
-
Small human pilot study in women with interstitial cystitis that reported symptom changes after BPC-157 given into the bladder.
Altern Ther Health Med, 2024 PubMed
-
Small retrospective human report of BPC-157 injected into the knee for various kinds of knee pain, with most patients reporting improvement.
Altern Ther Health Med, 2021 PubMed
-
Preclinical safety testing of BPC-157 in mice, rats and other species, used to support starting a clinical study.
Regul Toxicol Pharmacol, 2020 PubMed
-
Rat Achilles tendon study, with cultured tendon cells, reporting faster tendon healing with BPC 157.
J Orthop Res, 2003 PubMed
-
Cartilage-cell culture study reporting that peptides AED and CPC normalized secretion of aging-associated inflammatory molecules.
Adv Gerontol, 2023 PubMed
-
Human stem cell study reporting that the studied peptides stimulated cartilage-forming (chondrogenic) differentiation.
Adv Gerontol, 2023 PubMed
-
Human mesenchymal stem cell study reporting that short peptides at nanomolar levels changed expression of aging-related genes.
Mol Biol Rep, 2020 PubMed
-
Human dental stem cell study reporting increased early-neuron markers after treatment with short peptides.
Int J Immunopathol Pharmacol, 2019 PubMed
-
Cell study of aging skin fibroblasts reporting that several short peptides lowered MMP-9 and raised markers of cell renewal.
Bull Exp Biol Med, 2016 PubMed
-
Rodent kidney-tissue culture study reporting that short peptides increased cell proliferation and reduced cell death, more in young tissue.
Bull Exp Biol Med, 2015 PubMed
-
Kidney-cell culture and DNA-modeling study proposing that two tripeptides slow markers of aging by binding specific DNA sequences.
Adv Gerontol, 2014 PubMed
-
Thymus-cell culture study in which one peptide (AB-9) was reported to affect proliferation, differentiation and cell death during aging.
Bull Exp Biol Med, 2011 PubMed
-
Scoping review of thymosin beta-4 and TB-500, noting human evidence concentrated in eye and wound settings and limited direct TB-500 data.
Preprints.org, 2026 Europe PMC
-
Mouse and human study reporting that recombinant thymosin beta-4 improved ischemic cardiac dysfunction in an ErbB2-dependent manner.
Cardiovasc Res, 2025 PubMed
-
Randomized human trial reporting that thymosin beta-4 (RGN-259) eye drops promoted healing and comfort in neurotrophic keratopathy.
Int J Mol Sci, 2022 PubMed
-
First-in-human phase I trial of recombinant thymosin beta-4 describing its pharmacokinetics and lack of accumulation.
J Cell Mol Med, 2021 PubMed
-
Phase 2 randomized human trial reporting that thymosin beta-4 eye drops improved signs and symptoms of severe dry eye.
Cornea, 2015 PubMed
-
Mouse fracture study reporting that thymosin beta-4 enhanced bone healing.
J Orthop Res, 2014 PubMed
-
Randomized human phase I study reporting that intravenous thymosin beta-4 was well tolerated across a range of doses.
Ann N Y Acad Sci, 2010 PubMed
-
Phase 2 human trial reporting an acceptable safety profile for thymosin beta-4 in venous ulcers, with suggestive efficacy.
Ann N Y Acad Sci, 2010 PubMed
-
Human compassionate-use study reporting reduced irritation and healing of chronic corneal defects with thymosin beta-4.
Ann N Y Acad Sci, 2010 PubMed
-
Systematic review and network meta-analysis reporting that PTH1 receptor agonists such as teriparatide reduced fracture risk.
Osteoporos Int, 2025 PubMed
-
Meta-analysis reporting that teriparatide reduced fracture risk more than bisphosphonates in osteoporosis.
Arch Osteoporos, 2024 PubMed
-
Meta-analysis reporting greater reductions in vertebral fractures with teriparatide than bisphosphonates in postmenopausal osteoporosis.
Altern Ther Health Med, 2024 PubMed
-
Systematic review of human treatments to prevent fractures in low bone mass, including teriparatide among effective options.
Ann Intern Med, 2023 PubMed
-
Human observational surveillance study of osteosarcoma incidence among teriparatide-treated patients; estimates were imprecise due to few cases.
Bone, 2022 PubMed
-
Human case series reporting calciphylaxis possibly associated with teriparatide in patients with risk factors.
Osteoporos Int, 2022 PubMed
-
Randomized human trial reporting fewer new fractures with teriparatide than risedronate in postmenopausal women with severe osteoporosis.
Lancet, 2018 PubMed
-
Randomized human trial reporting that parathyroid hormone (1-34), i.e., teriparatide, reduced fractures and increased bone density in postmenopausal osteoporosis.
N Engl J Med, 2001 PubMed
-
In a rat model of heart and kidney stress, the EPO-derived peptide ARA290 was reported to reduce cardiac inflammation and structural changes.
Front Cardiovasc Med, 2022 PubMed
-
Randomized human trial in sarcoidosis-related small fiber neuropathy reporting increased corneal and skin nerve fiber counts with cibinetide (ARA-290).
Invest Ophthalmol Vis Sci, 2017 PubMed
-
Randomized human trial in type 2 diabetes with neuropathy reporting changes in metabolic control and corneal nerve measures with ARA 290.
Mol Med, 2015 PubMed
-
Randomized human study testing ARA290 on emotional processing; effects were mixed and did not clearly indicate an antidepressant profile.
Eur Neuropsychopharmacol, 2015 PubMed
-
Review of ARA 290 research in sarcoidosis-related small fiber neuropathy, covering safety and symptom data from human trials.
Expert Opin Investig Drugs, 2014 PubMed
-
Rat study of kidney ischemia/reperfusion injury reporting that ARA290 lessened tissue damage and inflammation.
J Transl Med, 2013 PubMed
-
In a rat nerve-inflammation (neuritis) model, ARA290 was reported to reverse touch hypersensitivity.
Neuroscience, 2013 PubMed
-
Randomized human trial in sarcoidosis reporting that ARA 290 appeared safe and reduced neuropathic symptom scores.
Mol Med, 2012 PubMed
-
Randomized human study of oral glutathione showing a non-significant trend toward lower oxidative stress markers.
Acta Dermatovenerol Alp Pannonica Adriat, 2025 PubMed
-
Systematic review of glutathione for skin lightening and melasma, advising against intravenous use due to weak evidence and side effects.
Int J Dermatol, 2025 PubMed
-
Randomized human trial of oral L-cystine plus glutathione reporting skin lightening over 12 weeks.
J Cosmet Dermatol, 2022 PubMed
-
Meta-analysis of human trials reporting that glutathione may slightly improve motor scores in Parkinson's disease.
Exp Ther Med, 2021 PubMed
-
Phase IIb human trial of intranasal glutathione in Parkinson's disease finding no advantage over placebo after three months.
J Parkinsons Dis, 2017 PubMed
-
Randomized human trial reporting that daily oral glutathione supplements raised glutathione levels in blood and other body stores.
Eur J Nutr, 2015 PubMed
-
Randomized placebo-controlled human study reporting slight skin lightening with oral glutathione in some participants; long-term safety not established.
J Dermatolog Treat, 2012 PubMed
-
Randomized human trial in advanced gastric cancer reporting less cisplatin-related nerve damage with glutathione, without reducing chemotherapy effect.
J Clin Oncol, 1995 PubMed
-
Mouse and cell study reporting that KPV reduced fat-cell formation through ROS-related signaling.
Tissue Cell, 2026 PubMed
-
Human skin-cell and 3D-skin study reporting that KPV reduced fine-dust-induced cell death and inflammation.
Tissue Cell, 2025 PubMed
-
Rat study reporting that a KPV-containing hydrogel lowered inflammatory cytokines in a colitis model.
ACS Biomater Sci Eng, 2021 PubMed
-
Mouse colitis study reporting that orally delivered KPV nanoparticles reduced gut damage and inflammation.
Mol Ther, 2017 PubMed
-
Human airway-cell study reporting that KPV and gamma-MSH suppressed inflammatory NF-kB signaling via the MC3R receptor.
Int J Physiol Pathophysiol Pharmacol, 2012 PubMed
-
Review of alpha-MSH-related tripeptides including KPV, covering their biochemistry and anti-inflammatory effects.
Endocr Rev, 2008 PubMed
-
Mouse colitis study reporting significant anti-inflammatory effects of the melanocortin-derived tripeptide KPV.
Inflamm Bowel Dis, 2008 PubMed
-
Mouse study reporting that the tripeptide KPV, taken up via the PepT1 transporter, reduced intestinal inflammation.
Gastroenterology, 2008 PubMed
-
Mouse study distinguishing the anti-inflammatory effect of the C-terminal MSH tripeptide KPV from that of full-length MSH.
J Pharmacol Exp Ther, 2003 PubMed
-
In-depth review of LL-37's antibiofilm properties, noting open questions about its safety and effectiveness in the body.
World J Microbiol Biotechnol, 2023 PubMed
-
Randomized double-blind human trial reporting that LL-37 cream improved healing of mildly infected diabetic foot ulcers.
Arch Dermatol Res, 2023 PubMed
-
Human-cell study suggesting that LL-37 could promote local melanoma invasion by activating tumor and immune cells.
Cancers (Basel), 2023 PubMed
-
Multicenter randomized human trial that found no significant overall difference in healing of hard-to-heal venous leg ulcers with LL-37.
Wound Repair Regen, 2021 PubMed
-
Mouse pressure-ulcer study reporting that an LL-37-loaded chitosan hydrogel promoted deep tissue healing.
Mil Med Res, 2020 PubMed
-
Human case report of skin toxicity during experimental LL-37 injection therapy for melanoma, which resolved after stopping treatment.
J Cutan Pathol, 2018 PubMed
-
Randomized human trial reporting that topical LL-37 was safe and improved healing of hard-to-heal venous leg ulcers.
Wound Repair Regen, 2014 PubMed
-
Review of LL-37 as a possible treatment for polymicrobial wound infections.
Front Immunol, 2013 PubMed
-
Review describing "poptosis," a peptide-induced membrane-pore mechanism by which PNC-27 kills cancer cells.
Biomedicines, 2024 PubMed
-
Mouse study reporting that PNC-27 selectively killed colon cancer stem-like cells by binding membrane H/MDM-2.
Anticancer Res, 2021 PubMed
-
Mouse leukemia study reporting that PNC-27 targeted membrane HDM2 to kill acute myeloid leukemia cells while sparing normal blood stem cells.
Leukemia, 2020 PubMed
-
Human-cell study reporting that PNC-27 targeting membrane HDM-2 caused necrosis in leukemia cells but not normal blood cells.
Anticancer Res, 2020 PubMed
-
Mouse study reporting that PNC-27 improved the antitumor efficacy of a liposomal doxorubicin (Doxil) against HDM2-positive cancers.
Nanomedicine (Lond), 2017 PubMed
-
Mouse ovarian-cancer study reporting synergy between PNC-27 and paclitaxel.
Ann Clin Lab Sci, 2017 PubMed
-
Human cancer-cell study reporting PNC-27 activity against freshly isolated ovarian cancer cells.
Ann Clin Lab Sci, 2015 PubMed
-
Lab study describing how PNC-27 binds membrane HDM-2 and forms transmembrane channels to kill cancer cells.
Proc Natl Acad Sci U S A, 2010 PubMed
-
Cell study reporting that chondroitin sulfate on tumor cells mediated entry and cancer-cell killing by cell-penetrating peptides such as PNC-27.
J Biol Chem, 2010 PubMed
-
Human cancer-cell study of peptides from RAS-p21 and p53 proteins (PNC-27 family) that were cytotoxic to pancreatic tumor cells.
Cancer Ther, 2007 PubMed
-
Human study in severe COVID-19 reporting that thymalin lowered fibrinogen, LDH and D-dimer levels.
Adv Gerontol, 2022 PubMed
-
Human cell study reporting that thymalin stimulated differentiation of hematopoietic stem cells.
Bull Exp Biol Med, 2020 PubMed
-
Rat study reporting tumor regression and anti-stress adaptation with thymalin under activation therapy.
Bull Exp Biol Med, 2018 PubMed
-
Russian-language human study in post-cesarean endometritis comparing thymalin, thymogen and roncoleukin on immunity and clotting.
Байкальский медицинский журнал, 2012 CyberLeninka
-
Russian-language human study on the immunomodulator thymalin in children with chronic lung disease.
Acta Biomedica Scientifica, 2005 CyberLeninka
-
Human study reporting that the pineal and thymus peptides epithalamin and thymalin were associated with longer survival in older people.
Neuro Endocrinol Lett, 2003 PubMed
-
Human study reporting improvements in general well-being and parkinsonian symptoms when thymalin was added to treatment.
Lik Sprava, 1999 PubMed
-
Human study describing a combined protocol, including thymalin, to prevent complications in children with diffuse purulent peritonitis.
Khirurgiia (Mosk), 1994 PubMed
-
Human study in children reporting immune changes during thymalin treatment of herpetic stomatitis.
Stomatologiia (Mosk), 1994 PubMed
-
Randomized human study reporting that a thymogen-based product reduced acute inflammation in the stomach lining on endoscopy.
Ter Arkh, 2023 PubMed
-
Randomized human study reporting that alpha-glutamyl-tryptophan (thymogen) supported tissue repair in chronic atrophic gastritis.
Arkh Patol, 2023 PubMed
-
Human prostate-cancer screening-model study reporting that the antiangiogenic agent IM862 (thymogen-related) was well tolerated but not superior.
Prostate, 2007 PubMed
-
Phase II human trial concluding that single-agent IM862 should not be further developed for metastatic kidney cancer, despite lower VEGF.
Br J Cancer, 2004 PubMed
-
Mouse study reporting that the antitumor activity of the dipeptide L-Glu-L-Trp depended on natural killer cell activity.
Int J Cancer, 2003 PubMed
-
Mouse and rat study reporting that the dipeptide L-Glu-L-Trp (thymogen) slowed aging markers and lowered spontaneous tumor incidence.
Biogerontology, 2000 PubMed
-
Systematic review and meta-analysis suggesting thymosin alpha-1 may reduce 28-day mortality in sepsis, with variable effects.
Front Cell Infect Microbiol, 2025 PubMed
-
Multicenter randomized human trial (TESTS) finding no clear evidence that thymosin alpha-1 reduced 28-day mortality in sepsis.
BMJ, 2025 PubMed
-
Meta-analysis reporting that thymosin alpha-1 helped rebalance immune cells and reduce immune suppression in severe acute pancreatitis.
Front Immunol, 2025 PubMed
-
Pilot randomized human trial reporting that thymosin alpha-1 raised CD4 T-cell counts faster than standard care in hospitalized COVID-19 patients.
J Infect Dis, 2023 PubMed
-
Systematic review and meta-analysis suggesting thymosin alpha-1 may reduce mortality in moderate-to-critical COVID-19, pending more trials.
Inflammopharmacology, 2023 PubMed
-
Human study in hemodialysis patients reporting that thymosin alpha-1 (Zadaxin) enhanced the immune response to a pandemic H1N1 flu vaccine.
Vaccine, 2012 PubMed
-
Randomized human trial reporting numerically higher survival and tumor response when thymalfasin was added to chemoembolization for liver cancer.
Hepatol Int, 2009 PubMed
-
Meta-analysis comparing thymosin alpha-1 with interferon alpha in chronic hepatitis, reporting delayed but sustained benefits.
Antiviral Res, 2008 PubMed
-
Aged-mouse study reporting that thymulin restrained age-related myeloid inflammation and improved cancer immunotherapy response.
Nat Commun, 2026 PubMed
-
Mouse multiple-sclerosis (EAE) model study reporting that thymulin plus peroxiredoxin 6 restored blood-brain-barrier conditions.
Arch Biochem Biophys, 2023 PubMed
-
Mouse study reporting that thymulin and the antioxidant enzyme peroxiredoxin 6 had protective, anti-inflammatory effects in type 1 diabetes.
Int J Immunopathol Pharmacol, 2021 PubMed
-
Mouse study reporting that nanoparticle-based thymulin gene therapy reversed key pathology in an experimental disease model.
Sci Adv, 2020 PubMed
-
Mouse multiple-sclerosis model study reporting that nanoparticle-bound thymulin was more protective than free thymulin.
Int J Mol Sci, 2019 PubMed
-
Rat study reporting that thymulin reduced inflammatory pain by modulating spinal microglia and inflammatory signaling.
Int Immunopharmacol, 2019 PubMed
-
Mouse sepsis study reporting that thymulin, free or in nanoparticles, suppressed inflammation.
PLoS One, 2018 PubMed
-
Russian-language rat study reporting that thymic peptides, including thymulin, reduced the opioid component of immobilization-induced analgesia.
Вестник Российской академии медицинских наук, 2015 CyberLeninka
-
Review of the physiology and therapeutic potential of the thymic peptide thymulin, including its anti-inflammatory properties.
Curr Pharm Des, 2014 PubMed
-
Review of thymulin and its analog as a potential analgesic, including effects on hippocampal NF-kB signaling.
Ann N Y Acad Sci, 2006 PubMed
-
Systematic review and meta-analysis suggesting aviptadil (VIP) may aid oxygenation in ARDS, though evidence of significant benefit is lacking.
Indian J Crit Care Med, 2025 PubMed
-
Randomized human study reporting that inhaled aviptadil was well tolerated and may speed respiratory recovery in COVID-19.
Med Princ Pract, 2025 PubMed
-
Human observational study reporting that intracavernosal aviptadil with phentolamine helped most men with refractory erectile dysfunction.
J Sex Med, 2025 PubMed
-
Human observational study reporting improved clinical outcomes with aviptadil in severe viral-related ARDS without adverse effects.
Indian J Crit Care Med, 2024 PubMed
-
Randomized human trial reporting that intravenous aviptadil (VIP) plus remdesivir did not significantly improve outcomes in COVID-19 respiratory failure.
Lancet Respir Med, 2023 PubMed
-
Randomized human trial of intravenous aviptadil (VIP) in critical COVID-19 that did not meet its primary endpoint.
Crit Care Med, 2022 PubMed
-
Human study reporting a trend toward improved oxygenation with inhaled VIP (aviptadil) in pulmonary hypertension.
Eur Respir J, 2008 PubMed
-
Meta-analysis comparing many approaches for vascular cognitive impairment in humans; certainty of evidence was generally low.
Alzheimers Dement, 2025 PubMed
-
Human study of Cerebrolysin added early to clot-removal therapy in stroke, reporting fewer symptomatic brain bleeds.
BMC Neurol, 2023 PubMed
-
Cochrane review of human stroke trials concluding Cerebrolysin probably makes no difference to serious adverse events, with uncertain benefit on death.
Cochrane Database Syst Rev, 2023 PubMed
-
Systematic review and meta-analysis of human traumatic brain injury studies reporting better clinical outcomes with Cerebrolysin.
Brain Sci, 2023 PubMed
-
Prospective meta-analysis of the human CAPTAIN trials reporting that Cerebrolysin was safe and associated with better outcomes after moderate-severe brain injury.
Neurol Sci, 2021 PubMed
-
Randomized human trial in moderate-severe traumatic brain injury reporting better overall outcome with Cerebrolysin on a multi-measure analysis.
Neurol Sci, 2020 PubMed
-
Randomized human pilot trial (CAPTAIN I) in traumatic brain injury suggesting better outcomes with Cerebrolysin, pending a larger trial.
Neurol Sci, 2020 PubMed
-
Cochrane review concluding the human evidence for Cerebrolysin in vascular dementia is weak and larger trials are needed.
Cochrane Database Syst Rev, 2019 PubMed
-
Meta-analysis of human stroke trials examining Cerebrolysin and functional recovery; it did not raise the rate of adverse events.
Drug Des Devel Ther, 2017 PubMed
-
Randomized placebo-controlled human trial in early stroke rehabilitation reporting better motor function and global outcome with Cerebrolysin.
Stroke, 2016 PubMed
-
Meta-analysis of randomized human trials in mild-to-moderate Alzheimer's disease reporting an overall favorable effect and benefit-risk balance for Cerebrolysin.
Dement Geriatr Cogn Disord, 2015 PubMed
-
Randomized human stroke trial in Asia with a neutral main result; a favorable trend was seen in more severe cases.
Stroke, 2012 PubMed
-
Randomized human trial in moderate Alzheimer's disease reporting dose-specific effects of Cerebrolysin on cognitive and global measures.
Eur J Neurol, 2011 PubMed
-
Rat study reporting that dermorphin pretreatment blocked the breathing pause caused by an intravenous fentanyl injection.
Toxicol Appl Pharmacol, 2026 PubMed
-
Review revisiting dermorphin, an opioid peptide once tested for post-surgical pain, and calling for new safety studies.
J Pain Res, 2018 PubMed
-
Horse study describing how dermorphin is absorbed, cleared and acts after dosing, with relevance to racing drug testing.
J Vet Pharmacol Ther, 2015 PubMed
-
Review of chemically modified dermorphin tetrapeptides and their opioid receptor profiles in lab and animal work.
Peptides, 2011 PubMed
-
Review of the pharmacology of opioid peptides from amphibian skin, including dermorphin and deltorphins.
Peptides, 2000 PubMed
-
Review of the dermorphin peptide family, including rodent data on pain-blocking potency and tolerance.
Gen Pharmacol, 1996 PubMed
-
Rat brain-slice study reporting that dermorphin made hippocampal neurons more excitable, an effect blocked by naloxone.
Eur J Pharmacol, 1994 PubMed
-
Randomized human study comparing spinal (intrathecal) dermorphin with morphine for pain after surgery.
Peptides, 1985 PubMed
-
Rat Huntington's-like model study in which an angiotensin IV analog did not prevent symptoms.
J Huntingtons Dis, 2024 PubMed
-
Alzheimer's model mouse study reporting that dihexa improved memory tests and reduced inflammation through PI3K/AKT signaling.
Brain Sci, 2021 PubMed
-
Rat nerve-repair study reporting better limb function recovery with stem cells, G-CSF and/or dihexa.
Ann Med Surg (Lond), 2021 PubMed
-
Systematic review of animal experiments on angiotensin IV and angiotensin-(1-7) in memory and learning models.
Neurosci Biobehav Rev, 2018 PubMed
-
Zebrafish study reporting that dihexa, an HGF mimetic, protected sensory hair cells from aminoglycoside antibiotic damage.
Front Cell Neurosci, 2015 PubMed
-
Retracted
Retracted rat study proposing that angiotensin IV-derived peptides such as dihexa act through the HGF/c-Met pathway.
J Pharmacol Exp Ther, 2014 PubMed
-
Rat study describing chemical changes that made angiotensin IV analogs stable and orally active, and their effects in memory tests.
J Pharmacol Exp Ther, 2013 PubMed
-
Rat study of chronic low brain blood flow reporting that orexin A reduced neuroinflammation and cognitive problems by rebalancing microglia.
Exp Neurol, 2025 PubMed
-
Mouse study of sepsis-associated brain injury reporting that intranasal orexin-A protected the blood-brain barrier.
J Neuroinflammation, 2024 PubMed
-
Systematic review of human studies reporting that orexin treatment of narcolepsy type 1 reduced abnormal REM transitions.
Cureus, 2024 PubMed
-
Pilot human study in healthy men reporting that intranasal orexin A modulated sympathetic vascular tone.
J Neurophysiol, 2022 PubMed
-
Randomized human study reporting improved divided-attention performance after intranasal orexin-A in narcolepsy.
Behav Brain Res, 2014 PubMed
-
Randomized human pilot study reporting functional effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
Sleep Med, 2011 PubMed
-
Randomized human study reporting that intranasal orexin A restored sense of smell in narcolepsy with cataplexy.
Brain, 2008 PubMed
-
Monkey study reporting that systemic and nasal orexin-A reduced sleep-deprivation effects on performance, with nasal delivery more effective.
J Neurosci, 2007 PubMed
-
Rat brain study examining how orexins modulated electrically evoked seizure-like hippocampal activity.
Acta Neurobiol Exp (Wars), 2026 PubMed
-
Mouse study reporting that orexin B reduced cerebral aneurysm formation via anti-inflammatory mechanisms.
CNS Neurosci Ther, 2026 PubMed
-
Mouse sepsis study reporting that orexin B lessened lung injury by protecting blood-vessel lining cells.
Biotechnol Appl Biochem, 2025 PubMed
-
Mouse Parkinson's-model study reporting that orexin B protected dopamine neurons against MPTP-induced damage.
Mol Biol Rep, 2024 PubMed
-
Rat neuropathic-pain study reporting that orexin B reduced pain and inflammatory signaling.
Neuropeptides, 2024 PubMed
-
Pig fat-cell study reporting that orexin B reduced the proliferation and fat-forming differentiation of stem cells.
Domest Anim Endocrinol, 2021 PubMed
-
Mouse Parkinson's-model study reporting that orexin-B excited dopamine neurons and improved motor measures.
Neurosci Lett, 2021 PubMed
-
Rat and human study reporting that cardiac orexin-B/OX2R signaling was linked to heart protection and heart-failure severity.
Clin Sci (Lond), 2018 PubMed
-
Rat retina study examining how orexin-B modulated signaling between retinal nerve cells.
Neuropharmacology, 2018 PubMed
-
Review of the roles of orexins in regulating sleep and wakefulness.
Neurosci Res, 2017 PubMed
-
Pig study reporting that an intramuscular injection of porcine orexin increased feed intake in young animals.
Domest Anim Endocrinol, 1999 PubMed
-
Mouse study of a CNTF-based peptide mimetic in an Alzheimer's model, examining treatment timing and duration.
J Neurodev Disord, 2024 PubMed
-
Review of P021, a neurotrophic peptide compound, and its preclinical potential for Alzheimer's and related disorders.
Biomolecules, 2022 PubMed
-
Mouse study reporting that neurotrophic peptide P021 given in early postnatal development prevented Alzheimer-like pathology.
J Alzheimers Dis, 2021 PubMed
-
Mouse study reporting that prenatal-to-early-postnatal P021 treatment prevented Alzheimer-like behavior and pathology.
Alzheimers Res Ther, 2020 PubMed
-
Aged-rat and Alzheimer's-model mouse study reporting that chronic P021 reduced age-related macular degeneration-like changes.
Front Aging Neurosci, 2019 PubMed
-
Mouse model study reporting that early P021 treatment rescued developmental delay and Alzheimer-like memory deficits.
Sci Rep, 2017 PubMed
-
Mouse Alzheimer's-model study reporting that P021 prevented amyloid and tau pathology and cognitive deficits when started early.
J Alzheimers Dis, 2017 PubMed
-
Aged-rat study reporting that P021 lowered elevated tau in cerebrospinal fluid without a detectable immune reaction.
J Alzheimers Dis, 2015 PubMed
-
Mouse Alzheimer's-model (3xTg-AD) study reporting that oral P021 improved cognition, neurogenesis and synaptic plasticity.
Neurobiol Dis, 2014 PubMed
-
Aged-rat study reporting that P021 improved cognitive aging and reduced a brain metabolite marker.
Neurobiol Aging, 2014 PubMed
-
Mouse study reporting that an adamantane-containing neurotrophic peptide (P21/P021) improved learning, memory and neurogenesis.
FEBS Lett, 2010 PubMed
-
Cell study reporting that sortilin-derived peptides (PE 22-28 family) supported pancreatic beta-cell survival and proliferation via CREB signaling.
Pharmacol Res, 2021 PubMed
-
Review of TREK-1 blockers for depression, focusing on spadin and its shortened analogs.
Pharmacol Ther, 2019 PubMed
-
Mouse stroke study reporting that a mini-spadin peptide aided stroke recovery and reduced post-stroke depression via neurogenesis and synaptogenesis.
Neuropharmacology, 2019 PubMed
-
Mouse study reporting that shortened spadin analogs (including PE 22-28) gave stronger TREK-1 channel inhibition, longer stability and antidepressant-like effects.
Front Pharmacol, 2017 PubMed
-
Mouse study presenting a short-term assay that identified healthspan benefits and early toxicity of longevity interventions, including pinealon.
bioRxiv, 2026 Europe PMC
-
Human induced-neuron study reporting that short peptides partly protected cells from age-related changes and promoted dendrite growth.
Int J Mol Sci, 2024 PubMed
-
Russian-language study in rhesus monkeys examining pinealon's effect on cognitive rehabilitation during aging.
Вестник Московского университета. Серия 23. Антропология, 2019 CyberLeninka
-
Human geriatric study reporting that the peptides pinealon and vesugen were applied as geroprotectors in patients with multiple chronic illnesses.
Adv Gerontol, 2015 PubMed
-
Human study in locomotive-crew workers reporting improved biological-age and adaptation measures after two weeks of pinealon.
Adv Gerontol, 2012 PubMed
-
Human study in professional truck drivers reporting the best effect on neurotic symptoms when pinealon and vesugen were combined.
Adv Gerontol, 2012 PubMed
-
Rat study reporting that pinealon given to pregnant rats protected offspring against effects of prenatal high homocysteine.
Int J Clin Exp Med, 2012 PubMed
-
Rat study of short peptides before carotid artery occlusion, reporting behavioral effects of cortexin and pinealon.
Adv Gerontol, 2011 PubMed
-
Cell study reporting that pinealon increased cell viability by lowering free-radical levels and supporting proliferation.
Rejuvenation Res, 2011 PubMed
-
Rat study reporting that selank, a tuftsin analog, reduced signs of morphine withdrawal.
Bull Exp Biol Med, 2022 PubMed
-
Human brain-imaging study using functional connectivity to study the effects of selank and semax.
Dokl Biol Sci, 2020 PubMed
-
Russian-language human study in atopic dermatitis patients reporting that selank eased anxiety and cognitive-affective symptoms.
Человек и его здоровье, 2020 CyberLeninka
-
Rat study reporting that selank protected against alcohol-induced memory impairment by regulating brain BDNF.
Bull Exp Biol Med, 2019 PubMed
-
Lab study proposing a molecular mechanism for the anti-anxiety heptapeptide selank.
Protein Pept Lett, 2018 PubMed
-
Rat chronic-stress study reporting that selank enhanced the anti-anxiety effect of diazepam.
Behav Neurol, 2017 PubMed
-
Rat Parkinson's-model study reporting that semax and selank affected behavior in 6-OHDA-lesioned rats.
Dokl Biol Sci, 2017 PubMed
-
Russian-language human study reporting good tolerability of selank in treating psychogenic anxiety.
Таврический журнал психиатрии, 2016 CyberLeninka
-
Russian-language human study reporting that combining benzodiazepines with selank broadened treatment options for anxiety-spectrum disorders.
Zh Nevrol Psikhiatr Im S S Korsakova, 2015 PubMed
-
Russian-language human study comparing selank with phenazepam for anxiety, reporting comparable anti-anxiety effects.
Zh Nevrol Psikhiatr Im S S Korsakova, 2014 PubMed
-
Mouse and rat study examining selank's effects on genetic and stress-provoked depression-like behavior.
Zh Vyssh Nerv Deiat Im I P Pavlova, 2008 PubMed
-
Russian-language human study of the peptide anxiolytic selank in generalized anxiety disorder, examining enkephalin-related mechanisms.
Zh Nevrol Psikhiatr Im S S Korsakova, 2008 PubMed
-
Mouse and rat spinal-cord-injury study reporting that semax aided recovery by acting on mu-opioid receptor signaling.
Br J Pharmacol, 2025 PubMed
-
Mouse Alzheimer's-model study reporting that semax and a derivative reduced amyloid deposits in the brain.
Acta Naturae, 2025 PubMed
-
Russian-language review of the oligopeptide semax in treating and rehabilitating ischemic stroke patients.
Zh Nevrol Psikhiatr Im S S Korsakova, 2024 PubMed
-
Russian-language human study reporting that semax raised BDNF and sped functional recovery in ischemic stroke.
Zh Nevrol Psikhiatr Im S S Korsakova, 2018 PubMed
-
Russian-language human study reporting psycho-emotional improvements when semax was added to antioxidant therapy in psoriasis.
Актуальные проблемы медицины, 2012 CyberLeninka
-
Russian-language human study reporting improved dermatology scores with semax added to standard atopic dermatitis therapy.
Человек и его здоровье, 2008 CyberLeninka
-
Russian-language human study reporting that semax improved quality-of-life measures in motor neuron disease patients.
Zh Nevrol Psikhiatr Im S S Korsakova, 2007 PubMed
-
Rat study reporting specific semax binding sites in the forebrain and increased BDNF, consistent with cognitive effects.
J Neurochem, 2006 PubMed
-
Russian-language human study reporting favorable recovery effects of semax in optic-nerve disease.
Vestn Oftalmol, 2000 PubMed
-
Russian-language human study reporting that semax influenced recovery in the acute phase of hemispheric ischemic stroke.
Zh Nevrol Psikhiatr Im S S Korsakova, 1997 PubMed
-
Cochrane review of human trials of prenatal TRH added to corticosteroids for preterm birth, noting possible worse infant outcomes.
Cochrane Database Syst Rev, 2013 PubMed
-
Human preliminary study reporting that TRH (protirelin) may ease cancer-related fatigue, with no unexpected side effects.
J Int Med Res, 2009 PubMed
-
Randomized human trial reporting no added benefit of antenatal TRH over glucocorticoid alone for preventing preterm lung disease.
N Engl J Med, 1998 PubMed
-
Randomized human study reporting rapid mood improvement after intrathecal protirelin (TRH) in treatment-refractory depression.
Arch Gen Psychiatry, 1997 PubMed
-
Randomized human trial reporting that prenatal TRH reduced chronic lung disease in very-low-birthweight infants.
Lancet, 1992 PubMed
-
Randomized human study of TRH (protirelin) in depressed alcoholic men, describing behavioral and endocrine responses.
Arch Gen Psychiatry, 1979 PubMed
-
Randomized human study reporting behavioral effects of protirelin (TRH) in schizophrenia.
Arch Gen Psychiatry, 1978 PubMed
-
Rat model of obstructive lung disease reporting less neutrophil inflammation and more normal cell makeup in the airway after bronchogen.
Ross Fiziol Zh Im I M Sechenova, 2017 PubMed
-
Human cell study linking short peptides to changes in gene promoter methylation and expression in aging pancreatic cells.
Biochemistry (Mosc), 2015 PubMed
-
Rat study of a chronic lung-injury model reporting that the tetrapeptide bronchogen reduced remodeling of bronchial lining tissue.
Bull Exp Biol Med, 2015 PubMed
-
Cell-culture study of aging human cells reporting that several short peptides each stimulated differentiation markers in a tissue-specific way.
Bull Exp Biol Med, 2012 PubMed
-
Lab biophysics study reporting that the peptide bronchogen binds DNA and alters its heat stability.
Bull Exp Biol Med, 2011 PubMed
-
Review of inflammation-related aging of cardiovascular cells, listing several peptides studied as possible modulators.
Cells, 2022 PubMed
-
Biochemistry study of how short peptides bind plant histones and histone–DNA complexes.
Biochemistry (Mosc), 2013 PubMed
-
Russian-language human clinical report on adding peptide bioregulators to treatment in elderly patients.
Наука о жизни и здоровье, 2012 CyberLeninka
-
Human fibroblast culture study comparing short peptides on markers of cell differentiation; one peptide (T-38) was most active.
Adv Gerontol, 2010 PubMed
-
Russian-language tumor-cell culture study of how cardiogen and peptide T-32 affect nuclear proteins involved in ribosome production.
Актуальные проблемы медицины, 2010 CyberLeninka
-
Rodent heart-tissue culture study reporting that cardiogen lowered p53 protein expression in cultured heart cells.
Adv Gerontol, 2009 PubMed
-
In aged rats with M-1 sarcoma, cardiogen was associated with slower tumor growth, which the authors judged was not a direct toxic effect on tumor cells.
Bull Exp Biol Med, 2009 PubMed
-
Rodent organ-culture study reporting tissue-specific growth stimulation by several short synthetic "bioregulator" peptides.
Adv Gerontol, 2006 PubMed
-
Russian-language rat tissue-culture study reporting that tripeptides increased growth of bronchial and lung tissue explants.
Интегративная физиология, 2025 CyberLeninka
-
Human immune-cell culture study reporting that short peptides lowered proliferation and inflammatory signaling in monocyte/macrophage cells.
Int J Mol Sci, 2022 PubMed
-
Russian-language study on isolated neurons from a freshwater snail, reporting that high concentrations of cortexin and cortagen suppressed sodium and calcium currents.
Обзоры по клинической фармакологии и лекарственной терапии, 2013 CyberLeninka
-
Rat study reporting that cortexin and cortagen limited oxidative stress and related brain changes after injury.
Eksp Klin Farmakol, 2011 PubMed
-
Study in chickens with the pituitary removed at hatching, describing effects of epithalon and cortagen on immune and clotting measures.
Adv Gerontol, 2008 PubMed
-
Rat study reporting that epithalon and cortagen lowered markers of lipid and protein oxidation.
Bull Exp Biol Med, 2007 PubMed
-
Mouse macrophage study reporting that short peptides had opposite effects on immune-signal production in resting versus stimulated cells.
Bull Exp Biol Med, 2006 PubMed
-
Rat brain study reporting that vilon, epithalon and cortagen changed interleukin-2 gene expression in hypothalamic regions.
Bull Exp Biol Med, 2005 PubMed
-
Lab study on lymphocytes from elderly people reporting chromatin loosening after treatment with several short peptides.
Bull Exp Biol Med, 2004 PubMed
-
Mouse study comparing heart gene-expression changes after cortagen, vilon, epitalon and melatonin.
Neuro Endocrinol Lett, 2004 PubMed
-
Rodent thymus-cell study comparing short peptides on cell activation and signaling; cortagen showed no such effect.
Bull Exp Biol Med, 2002 PubMed
-
Rodent spleen-cell study reporting that interleukin-2 gene activity varied with the type, dose and timing of short peptides.
Bull Exp Biol Med, 2002 PubMed
-
Rat tissue-explant study reporting that several synthetic peptides stimulated growth in a tissue-specific pattern.
Bull Exp Biol Med, 2001 PubMed
-
Rat study reporting faster regrowth of nerve fibers after sciatic nerve injury with cortagen.
Bull Exp Biol Med, 2000 PubMed
-
Russian-language review of how thymus-derived peptides such as thymogen and crystagen affect spleen immune cells with aging.
Adv Gerontol, 2014 PubMed
-
Preprint review of epitalon and epithalamin research, concluding the compounds show biological activity but remain clinically unproven.
Preprints.org, 2026 Europe PMC
-
Human cell-line study reporting that epitalon lengthened telomeres, via telomerase in normal cells and partly via ALT in cancer cells.
Biogerontology, 2025 PubMed
-
Cattle egg-cell (oocyte) lab study reporting higher maturation and post-thaw embryo development with epitalon.
Life Sci, 2025 PubMed
-
Human leukocyte study reporting that the AEDG peptide (epitalon) normalized expression of circadian clock genes.
Adv Gerontol, 2020 PubMed
-
Lifelong female rat study under different lighting conditions reporting longer survival in the oldest animals and fewer spontaneous tumors with epithalon.
Bull Exp Biol Med, 2007 PubMed
-
Russian-language human clinical study of epitalon's effect on immune measures in patients with burn injuries.
Медико-фармацевтический журнал «Пульс», 2007 CyberLeninka
-
Female C3H/He mouse study reporting slower spontaneous tumor development and no metastases in epitalon-treated mice.
In Vivo, 2006 PubMed
-
Study in aged rhesus monkeys reporting that pineal peptides restored some age-related hormone rhythms, with no effect in young monkeys.
Exp Gerontol, 2005 PubMed
-
Transgenic mouse study reporting slower aging markers, fewer breast tumors and longer lifespan with epithalon.
Bull Exp Biol Med, 2002 PubMed
-
Human clinical study in retinitis pigmentosa reporting improved retinal measures in most patients given epitalon.
Neuro Endocrinol Lett, 2002 PubMed
-
Glioblastoma cell and patient-data study linking the enzyme AGK to senescence and chemotherapy response; FOXO4-DRI was used as a lab tool.
Mol Carcinog, 2026 PubMed
-
Aged-mouse study reporting that FOXO4-DRI reduced senescence-related secretions in the testis and improved sperm production.
Exp Gerontol, 2024 PubMed
-
Mouse and rat study reporting that clearing senescent lung blood-vessel cells could worsen pulmonary hypertension.
Circulation, 2023 PubMed
-
Mouse lung-fibrosis study reporting that FOXO4-DRI targeted scar-forming myofibroblasts and reduced fibrosis.
J Cell Mol Med, 2022 PubMed
-
Lab study on expanded human cartilage cells reporting that FOXO4-DRI selectively removed senescent cells.
Front Bioeng Biotechnol, 2021 PubMed
-
Aged-mouse study reporting that FOXO4-DRI removed senescent testosterone-producing (Leydig) cells and improved testosterone output.
Aging (Albany NY), 2020 PubMed
-
Mouse study in fast-aging and naturally aged mice reporting that FOXO4-DRI cleared senescent cells and restored fitness, fur and kidney function.
Cell, 2017 PubMed
-
Review of a liver peptide complex and the KEDA tetrapeptide, reporting normalized immune and antioxidant measures in liver-disease models.
Adv Gerontol, 2020 PubMed
-
Lab study on cells from ductal breast cancer patients reporting protective effects of livagen with cobalt on genomic measures.
Georgian Med News, 2017 PubMed
-
Lab study on cells from older adults examining how a peptide bioregulator and cobalt ions affected nucleolar-organizing regions of chromosomes.
Georgian Med News, 2014 PubMed
-
Lab study on cells from atherosclerosis patients reporting that livagen, alone and with cobalt, affected chromatin.
Georgian Med News, 2014 PubMed
-
Lab study on cells from older adults examining how livagen modulated the radiation-induced adaptive response.
Georgian Med News, 2007 PubMed
-
Lab study on lymphocytes from older adults reporting that livagen with cobalt ions altered heterochromatin activation.
Ann N Y Acad Sci, 2007 PubMed
-
Lab study reporting that anti-aging peptide bioregulators, including livagen, reactivated chromatin in aged cells.
Georgian Med News, 2006 PubMed
-
Rat study reporting that oral livagen changed digestive-enzyme activity differently in young versus old animals.
Adv Gerontol, 2005 PubMed
-
Human-cell biochemistry study examining how livagen and epitalon affect enkephalin-degrading enzymes; no direct opioid-receptor interaction was found.
Izv Akad Nauk Ser Biol, 2003 PubMed
-
Organ-culture liver study reporting that the tetrapeptide livagen supported structure and function of liver cells.
Adv Gerontol, 2002 PubMed
-
Lab study on lymphocytes from older adults reporting that the livagen peptide reactivated ribosomal genes and loosened chromatin.
Bull Exp Biol Med, 2002 PubMed
-
Rat kidney-injury study reporting that the EDL peptide (ovagen) reduced markers of acute kidney damage.
Bull Exp Biol Med, 2017 PubMed
-
Study in old female rhesus monkeys reporting that the tetrapeptide pancragen improved impaired glucose tolerance.
Adv Gerontol, 2015 PubMed
-
Study in old monkeys reporting that pancragen improved pancreatic endocrine function, with effects partly persisting after stopping.
Adv Gerontol, 2014 PubMed
-
Cell study reporting that pancragen promoted differentiation of aging pancreatic cells, a possible anti-diabetic mechanism.
Bull Exp Biol Med, 2013 PubMed
-
Human pancreatic-cell study reporting that a tetrapeptide (pancragen) increased markers of functional activity in aging cells.
Adv Gerontol, 2012 PubMed
-
Human clinical study in elderly people examining pancragen for metabolic disturbances linked to reduced melatonin production.
Bull Exp Biol Med, 2011 PubMed
-
Rat diabetes study reporting that pancragen normalized blood glucose and some blood-vessel measures.
Bull Exp Biol Med, 2007 PubMed
-
Rat diabetes study reporting that the tetrapeptide pancragen improved pancreatic tissue structure and function.
Bull Exp Biol Med, 2007 PubMed
-
Rat study of alloxan-induced diabetes reporting that a tetrapeptide (pancragen) supported insulin biosynthesis.
Bull Exp Biol Med, 2005 PubMed
-
Lab study on cells from older adults reporting that the oligopeptide prostamax loosened chromatin during aging.
Georgian Med News, 2012 PubMed
-
Microcalorimetry study of human lymphocytes reporting that prostamax and low levels of copper and cadmium ions affected cell thermal stability.
Georgian Med News, 2009 PubMed
-
Lab study on human lymphocytes examining how the peptide prostamax affected heterochromatin and thermal stability of cell structures.
Biofizika, 2004 PubMed
-
Chicken study in hypophysectomized birds reporting effects of testagen-family peptides on thymus morphology.
Bull Exp Biol Med, 2013 PubMed
-
Chicken study reporting effects of the peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly (testagen family) on pituitary hormone activity and structure.
Bull Exp Biol Med, 2011 PubMed
-
Human HeLa-cell study examining how fluorescently labeled short peptides (including testagen) enter the nucleus and bind specific DNA sequences.
Biochemistry (Mosc), 2011 PubMed
-
Chicken study reporting that testagen-family peptides affected immunity and clotting after pituitary removal.
Patol Fiziol Eksp Ter, 2010 PubMed
-
Chicken study reporting effects of testagen-family tetrapeptides on thyroid structure and function.
Bull Exp Biol Med, 2008 PubMed
-
Rat liver-injury study reporting hepatoprotective effects of thymogen analogs, with a D-Ala analog most effective.
Bull Exp Biol Med, 2025 PubMed
-
Human-cell study reporting that alpha-glutamyl-tryptophan drugs (thymogen family) suppressed stimulated pro-inflammatory cytokine production.
Cell tissue biol, 2023 PubMed
-
Randomized human study reporting that preoperative thymogen helped restore cellular immunity in elderly patients with tumors.
Adv Gerontol, 2011 PubMed
-
Russian-language human study in post-cesarean endometritis patients comparing thymalin and thymogen effects on immunity and clotting.
Медицинская иммунология, 2011 CyberLeninka
-
Russian-language human study reporting improved immune measures and longer remission with thymogen and an antihistamine in chronic urticaria.
Вестник Авиценны, 2008 CyberLeninka
-
Phase III human trial reporting that the angiogenesis inhibitor IM862 (thymogen-related) was not effective against AIDS-related Kaposi's sarcoma.
J Clin Oncol, 2005 PubMed
-
Human study reporting that intranasal IM862 was well tolerated and showed antitumor activity in AIDS-related Kaposi's sarcoma.
J Clin Oncol, 2000 PubMed
-
Human study reporting that thymogen stimulated T-cell immunity in destructive pulmonary tuberculosis.
Voen Med Zh, 1999 PubMed
-
Human study reporting changes in immune and nonspecific reactivity with thymogen in chronic suppurative obstructive bronchitis.
Probl Tuberk, 1994 PubMed
-
Rat study reporting that the immunomodulator thymogen was associated with longer lifespan and lower tumor occurrence after radiation.
Vopr Onkol, 1992 PubMed
-
Human study reporting that thymogen had a desensitizing effect and clinical benefit in inflammatory female genital-tract disease.
Akush Ginekol (Mosk), 1992 PubMed
-
Russian-language lab study comparing vesugen and vesilute on recovery of thymus function during aging.
Клиническая геронтология, 2010 CyberLeninka
-
Russian-language endothelial-cell study reporting that the KED peptide (vesugen) lowered adhesion/clotting-related proteins and stimulated protective ones.
Молекулярная медицина, 2018 CyberLeninka
-
Human observational comparison of geroprotective methods, assessing safety across biochemical and immune measures.
Adv Gerontol, 2016 PubMed
-
Russian-language human study of peptide bioregulators (vesugen) in chronic arterial insufficiency of the lower limbs.
Adv Gerontol, 2014 PubMed
-
Lab study reporting that short peptides activated cell renewal in aging vascular-cell cultures.
Bull Exp Biol Med, 2014 PubMed
-
Rat study comparing surgery, the immunomodulator vilon, and their combination for experimental endometriosis.
Bull Exp Biol Med, 2015 PubMed
-
Russian-language human study of vilon added to standard treatment of chronic generalized periodontitis in older patients.
Дальневосточный медицинский журнал, 2014 CyberLeninka
-
Russian-language human study of vilon in elderly patients with inoperable cancer, describing blood and immune-cell changes.
Дальневосточный медицинский журнал, 2008 CyberLeninka
-
Russian-language human study comparing thymalin, epithalamin and vilon on immunity in patients with complicated appendicitis.
Медицинская иммунология, 2008 CyberLeninka
-
Russian-language human study reporting that vilon affected immunity and clotting and reduced insulin needs in patients of different ages.
Adv Gerontol, 2007 PubMed
-
Russian-language human study in 37 patients reporting effects of the thymomimetic vilon in diffuse toxic goiter.
Дальневосточный медицинский журнал, 2007 CyberLeninka
-
Russian-language human study reporting that the thymomimetic vilon reduced disseminated intravascular coagulation in diabetes.
Adv Gerontol, 2006 PubMed
-
Russian-language human report on including the immunomodulator vilon in combined treatment of elderly cancer patients.
Adv Gerontol, 2005 PubMed
-
Mouse and rat study reporting that vilon stimulated apoptosis but blunted cyclophosphamide's inhibitory effect in tissue cultures.
Adv Gerontol, 2003 PubMed
-
Mouse study reporting that epitalon, and partly vilon, reduced spontaneous mammary tumor development and HER-2/neu expression.
Int J Cancer, 2002 PubMed
-
Rat study reporting that the peptide vilon roughly halved the incidence of induced bladder tumors.
Bull Exp Biol Med, 2001 PubMed
-
Mouse study reporting that long-term vilon administration had no unfavorable effects and influenced biological-age markers.
Bull Exp Biol Med, 2000 PubMed
-
Early-phase human trial in relapsed chronic lymphocytic leukemia that set a maximum tolerated acadesine dose and described its safety.
Cancer Chemother Pharmacol, 2013 PubMed
-
Large randomized trial in heart-bypass surgery patients; acadesine (AICAR) did not reduce the combined rate of death, stroke or heart failure.
JAMA, 2012 PubMed
-
Human study finding no direct effect of intravenous AICAR on glucose uptake, while heart rate rose and blood pressure fell.
J Clin Pharmacol, 2011 PubMed
-
Mouse study reporting that four weeks of AICAR raised metabolic gene activity and running endurance even in sedentary animals.
Cell, 2008 PubMed
-
Human study in people with type 2 diabetes reporting that intravenous AICAR lowered liver glucose output and blood glucose.
Diabetologia, 2008 PubMed
-
In healthy people, intravenous AICAR was reported to modestly raise whole-body glucose disposal; effects differed in type 2 diabetes.
Diabetes, 2007 PubMed
-
Meta-analysis of human surgery trials reporting fewer early heart attacks and cardiac deaths with acadesine given around bypass surgery.
JAMA, 1997 PubMed
-
Randomized trial in people with chronic stable angina; acadesine showed no effect on exercise-induced heart ischemia at any dose.
Cardiovasc Drugs Ther, 1994 PubMed
-
Mouse and computer-modeling study reporting that BAM15 reduced atherosclerosis and proposing several molecular targets.
Sci Rep, 2025 PubMed
-
Comparison of 15 mitochondrial uncouplers in cells and mice; BAM15 was reported to have the broadest tolerance and best metabolic effects in db/db mice.
Mol Metab, 2025 PubMed
-
Preprint in aged mice reporting that BAM15 improved skeletal muscle function and mitochondrial respiration in sarcopenia.
bioRxiv, 2025 Europe PMC
-
Diet-induced obese mouse study combining calorie restriction with BAM15, reporting weight loss with lean mass preserved.
Clin Sci (Lond), 2024 PubMed
-
Review of BAM15 as a mitochondrial uncoupler in disease research, noting delivery and solubility challenges.
Front Endocrinol (Lausanne), 2023 PubMed
-
Mouse sepsis study reporting that BAM15 reduced kidney injury and death, linked to effects on mitochondrial DNA release.
J Clin Invest, 2023 PubMed
-
In diabetic db/db mice, BAM15 and calorie restriction both improved metabolic measures, with BAM15 reported stronger on glucose control.
Mol Metab, 2023 PubMed
-
In aged obese mice, mitochondrial uncoupling with BAM15 was reported to preserve muscle mass and function via mitophagy-related changes.
J Cachexia Sarcopenia Muscle, 2022 PubMed
-
Mouse study reporting that BAM15 protected against diet-induced obesity and improved glucose control, partly independent of weight loss.
EMBO Mol Med, 2020 PubMed
-
In diet-induced obese mice, the mitochondrial uncoupler BAM15 was reported to reverse obesity and improve insulin sensitivity.
Nat Commun, 2020 PubMed
-
Mouse study of sepsis-related acute respiratory distress reporting that humanin-G protected mitochondrial function, partly via STAT3.
Am J Respir Cell Mol Biol, 2026 PubMed
-
Human muscle-cell study reporting that MOTS-c and humanin reduced steroid-induced muscle-cell atrophy.
Physiol Rep, 2026 PubMed
-
Rat retinal-degeneration study reporting that humanin-G changed gene expression and improved vision measures.
Sci Rep, 2026 PubMed
-
Rat kidney ischemia-reperfusion study reporting reduced injury with S14G-humanin via STAT3 and ERK signaling.
Exp Physiol, 2026 PubMed
-
Systematic review of humanin's roles in aging and age-related disease.
Biology (Basel), 2023 PubMed
-
Review of cell and animal studies on humanin in diabetes, covering insulin sensitivity and beta-cell survival.
World J Diabetes, 2022 PubMed
-
Mouse study of diabetes-induced heart dysfunction reporting protective effects of S14G-humanin.
Bioengineered, 2021 PubMed
-
Mouse triple-negative breast cancer study reporting that humanin promoted tumor progression, urging caution.
Sci Rep, 2020 PubMed
-
Worm and mouse study, with human data, reporting that the mitochondrial peptide humanin was linked to lifespan and healthspan.
Aging (Albany NY), 2020 PubMed
-
Mouse stroke study reporting that a humanin analog reduced brain damage through PI3K/Akt signaling.
Brain Res, 2008 PubMed
-
Mouse study reporting that the humanin derivative S14G-HN prevented memory impairment caused by amyloid-beta.
J Neurosci Res, 2005 PubMed
-
Phase 3 human trial reporting that HMTM (a methylene blue tau inhibitor) reduced brain atrophy markers at 52 weeks, though the main comparison was complicated.
J Prev Alzheimers Dis, 2026 PubMed
-
Randomized human trial supporting the hypothesis that low-dose LMTM might be effective as a stand-alone Alzheimer's treatment.
J Alzheimers Dis, 2018 PubMed
-
Randomized human brain-imaging study reporting that low-dose methylene blue modulated task-related and resting brain networks.
Brain Imaging Behav, 2017 PubMed
-
Randomized crossover human trial reporting that methylene blue added to usual treatment improved residual depression and anxiety in bipolar disorder.
Br J Psychiatry, 2017 PubMed
-
Randomized human trial reporting that the tau-aggregation inhibitor LMTM (a methylene blue derivative) did not benefit mild-to-moderate Alzheimer's as an add-on.
Lancet, 2016 PubMed
-
Randomized functional-MRI human study reporting that low-dose methylene blue increased brain activity on attention and memory tasks.
Radiology, 2016 PubMed
-
Systematic review of human cases describing serotonin syndrome when methylene blue interacts with serotonergic drugs.
Psychosomatics, 2010 PubMed
-
Human cell study reporting that MOTS-c activated metabolic signaling but reduced reparative stem-cell function, showing context-dependent effects.
Inflamm Regen, 2026 PubMed
-
Mouse and human study reporting that MOTS-c improved intrinsic muscle mitochondrial function via PGC-1α/AMPK signaling.
Free Radic Biol Med, 2026 PubMed
-
Mouse study describing MOTS-c as a mitochondrial-encoded, interferon-linked host-defense peptide that enhanced bacterial clearance by macrophages.
Elife, 2026 PubMed
-
Mouse cancer-cachexia (C26) study reporting that MOTS-c partly protected against muscle loss by modulating catabolic signaling.
Front Med (Lausanne), 2026 PubMed
-
Mouse study reporting that MOTS-c reduced immobilization-induced muscle wasting and fat infiltration.
Am J Physiol Endocrinol Metab, 2024 PubMed
-
Mouse study of gestational diabetes reporting that MOTS-c lowered high blood sugar and protected insulin-producing cells.
Pharmacol Res, 2022 PubMed
-
Mouse and human study reporting that exercise induces MOTS-c, linking it to age-related physical decline.
Nat Commun, 2021 PubMed
-
Mouse study reporting that the mitochondrial peptide MOTS-c improved metabolism and reduced diet- and age-related insulin resistance and obesity.
Cell Metab, 2015 PubMed
-
Systematic review of preclinical and clinical NAD+ research finding clear biological activity but inconclusive anti-aging benefit in people.
Ageing Res Rev, 2026 PubMed
-
Systematic review reporting that NADH supplementation appears safe with few side effects, while clinical benefits need more study.
Am J Physiol Endocrinol Metab, 2024 PubMed
-
Human clinical report describing NADH as a possible Parkinson's disease treatment, with better responses in younger, earlier-stage patients.
Acta Neurol Scand Suppl, 1993 PubMed
-
Systematic review of ERR activation as an "exercise mimetic," including compounds such as SLU-PP-332.
Rev Med Chil, 2026 PubMed
-
Cell study examining ERR targeting (as with SLU-PP-332) to counter inactivity-related muscle atrophy.
Front Physiol, 2025 PubMed
-
Mouse study reporting that a synthetic ERR agonist (SLU-PP-332) eased metabolic syndrome and obesity.
J Pharmacol Exp Ther, 2024 PubMed
-
Mouse heart-failure study reporting that pan-ERR agonists improved cardiac fatty-acid metabolism and protected against pressure overload.
Circulation, 2024 PubMed
-
Aged-mouse study reporting that ERR agonism reversed mitochondrial dysfunction and inflammation, acting as a calorie-restriction mimetic.
Am J Pathol, 2023 PubMed
-
Mouse study reporting that SLU-PP-332 triggered an ERRα-dependent acute aerobic-exercise gene program and enhanced endurance.
ACS Chem Biol, 2023 PubMed
-
Randomized human trial of topical elamipretide eye drops in Leber hereditary optic neuropathy; well tolerated but did not meet the vision endpoint.
Ophthalmology, 2024 PubMed
-
168-week open-label human study reporting sustained tolerability and functional and cardiac improvements with elamipretide in Barth syndrome.
Genet Med, 2024 PubMed
-
Randomized human trial (MMPOWER-3) reporting that elamipretide (SS-31) did not improve walking distance or fatigue in primary mitochondrial myopathy.
Neurology, 2023 PubMed
-
Phase 2/3 human trial with open-label extension reporting symptom improvements with daily elamipretide in Barth syndrome.
Genet Med, 2021 PubMed
-
Randomized crossover human trial reporting a meaningful improvement in walking distance after 4 weeks of elamipretide in mitochondrial myopathy.
J Cachexia Sarcopenia Muscle, 2020 PubMed
-
Randomized human trial reporting that elamipretide was well tolerated but did not improve left-ventricular volume in heart failure over 4 weeks.
J Card Fail, 2020 PubMed
-
Randomized placebo-controlled human trial reporting effects of a single elamipretide infusion in heart failure with reduced ejection fraction.
Circ Heart Fail, 2017 PubMed
-
Phase 2a human pilot trial reporting that elamipretide during kidney-artery stenting reduced hypoxia and improved kidney function.
Circ Cardiovasc Interv, 2017 PubMed
-
In marmoset monkeys (with supporting mouse data), ACE-031 was reported to increase muscle fiber size and contractile strength.
PLoS One, 2026 PubMed
-
Companion report of the marmoset monkey work, describing increased muscle mass and strength after ACE-031 treatment.
bioRxiv, 2025 PubMed
-
Randomized human trial in boys with Duchenne muscular dystrophy; trends in lean mass and walking distance were noted before the study was stopped over side effects.
Muscle Nerve, 2017 PubMed
-
Mouse study reporting that blocking ActRIIB signaling increased muscle fatigability and caused metabolic side effects.
Mol Ther, 2014 PubMed
-
Single-dose study in healthy postmenopausal women; ACE-031 was reported to be generally well tolerated and to increase muscle mass.
Muscle Nerve, 2013 PubMed
-
In mice, a soluble activin type IIB receptor (the ACE-031 approach) was reported to grow skeletal muscle across fiber types.
J Appl Physiol (1985), 2010 PubMed
-
Umbrella review of performance-enhancing drugs in healthy people; anabolic steroids, GH and EPO carried notable health risks.
Sports Health, 2024 PubMed
-
Systematic review and meta-analysis of human studies on EPO and athletic performance, calling for better-designed trials.
BMJ Open Sport Exerc Med, 2020 PubMed
-
Randomized human study in trained cyclists finding no change in microvascular function with EPO despite higher hematocrit.
Physiol Rep, 2018 PubMed
-
Randomized human trial in trained cyclists: EPO improved a lab maximal test but not submaximal or road-race performance.
Lancet Haematol, 2017 PubMed
-
Open-label randomized human study reporting fewer cases of acute mountain sickness with preventive EPO injections.
J Korean Med Sci, 2014 PubMed
-
Review of pure red cell aplasia caused by antibodies against EPO, covering diagnosis and treatment.
Przegl Lek, 2010 PubMed
-
Individual-patient meta-analysis reporting higher mortality and worse survival in cancer patients given EPO-type drugs.
Cochrane Database Syst Rev, 2009 PubMed
-
Systematic review of human data comparing epoetin and darbepoetin for chemotherapy-induced anemia, finding no clinically relevant differences.
Clin Ther, 2006 PubMed
-
Mouse and cell study linking follistatin to treatment-resistant prostate cancer and describing a follistatin-neutralizing approach.
Proc Natl Acad Sci U S A, 2026 PubMed
-
Mouse study reporting that follistatin gene delivery reduced atherosclerosis and promoted fat-tissue "browning."
Cells, 2026 PubMed
-
Mouse preprint reporting that combining VEGF plasmid and AAV-follistatin gene therapy increased local muscle size and capillary density.
bioRxiv, 2026 Europe PMC
-
Retracted
Retracted mouse study on intranasal and injectable gene therapy (including follistatin) for lifespan extension.
Proc Natl Acad Sci U S A, 2022 PubMed
-
Mouse study reporting that follistatin gene therapy reduced metabolic inflammation and protected against arthritis after joint injury.
Sci Adv, 2020 PubMed
-
Mouse model of FSHD muscular dystrophy reporting increased muscle mass and strength with AAV follistatin gene therapy.
JCI Insight, 2018 PubMed
-
Mouse study showing that changes to follistatin's N terminus altered its effects on muscle size and fat.
Exp Mol Med, 2017 PubMed
-
Phase 1/2a human gene-therapy trial in Becker muscular dystrophy reporting improved walking distance and muscle tissue changes with follistatin.
Mol Ther, 2015 PubMed
-
Review of follistatin gene therapy in Becker muscular dystrophy and its rationale as a muscle-growth enhancer.
J Neuromuscul Dis, 2015 PubMed
-
Nonhuman primate study reporting that follistatin gene delivery increased muscle size and strength without organ abnormalities.
Sci Transl Med, 2009 PubMed
-
Review of myostatin inhibition, focusing on follistatin gene therapy for muscle disease and its safety in animal studies.
Muscle Nerve, 2009 PubMed
-
Rat study in an HLA-B27 arthritis model reporting that MGF controlled inflammation and limited bone changes.
Arthritis Res Ther, 2025 PubMed
-
Rabbit ACL-injury study reporting that MGF accelerated ligament repair and improved injured-cell mobility.
Int J Mol Sci, 2022 PubMed
-
Rat osteoarthritis study reporting that MGF E peptide pretreatment slowed cartilage degeneration and supported collagen synthesis.
Int Immunopharmacol, 2021 PubMed
-
Rat tendon study reporting that the MGF E peptide promoted healing of injured tendon.
Biotechnol Lett, 2016 PubMed
-
Mouse heart study reporting that localized delivery of the MGF E-domain peptide improved cardiac mechanics after injury.
Biomaterials, 2015 PubMed
-
Lab study on osteosarcoma cells examining how the MGF E peptide affects their growth and signaling.
Oncol Lett, 2015 PubMed
-
Review of the biological activity of synthetic peptides based on the E domain of the IGF-1Ec (MGF) isoform.
Hormones (Athens), 2014 PubMed
-
Human muscle-cell study reporting that the MGF E peptide extended the proliferative lifespan of satellite cells.
Mech Ageing Dev, 2011 PubMed
-
Review of mechano-growth factor (MGF), an IGF-1 splice product, and its roles in tissue repair, satellite cells and aging.
Endocrinology, 2010 PubMed
-
Human prostate-tissue study reporting preferential MGF (IGF-1Ec) expression in cancerous tissue, suggesting a role in cancer biology.
Prostate, 2010 PubMed
-
Review of growth factors, muscle function and their potential misuse as doping agents.
Curr Opin Pharmacol, 2008 PubMed
-
Sheep heart-attack study reporting that the MGF E-domain protected heart muscle from ischemia and improved function.
Heart Lung Circ, 2008 PubMed
-
Systematic review and meta-analysis of human trials reporting that topical and intraurethral alprostadil improved erectile function versus placebo.
Andrology, 2025 PubMed
-
Randomized human comparison reporting that intracavernous alprostadil was more effective and better tolerated than an intraurethral form.
Urology, 2000 PubMed
-
Human study of injected alprostadil in diabetic men with erectile dysfunction, reporting frequent but mostly tolerable penile pain.
Eur Urol, 2000 PubMed
-
Randomized human study comparing injected and intraurethral alprostadil; the intraurethral form was less effective but rated easier to use.
BJU Int, 1999 PubMed
-
Randomized human trial after nerve-sparing prostate surgery reporting higher recovery of spontaneous erections with early alprostadil injections.
J Urol, 1997 PubMed
-
Placebo-controlled human trial reporting that transurethral alprostadil produced erections sufficient for intercourse in most participants.
Urology, 1996 PubMed
-
Randomized human trial of intracavernosal alprostadil in men with erectile dysfunction, reporting effective responses and tolerable side effects.
N Engl J Med, 1996 PubMed
-
Dairy cow study reporting a higher LH surge with a larger gonadorelin dose at the start of a breeding protocol.
J Dairy Sci, 2026 PubMed
-
Human observational study reporting that a triptorelin stimulation test performed similarly to the standard GnRH test for early puberty diagnosis.
Ann Pediatr Endocrinol Metab, 2024 PubMed
-
Systematic review of human studies on gonadotropins for inducing puberty in males with hypogonadotropic hypogonadism.
Eur J Endocrinol, 2024 PubMed
-
Human study in men with hypogonadotropic hypogonadism reporting earlier sperm production with a pulsatile gonadorelin pump than with cyclical gonadotropins.
Am J Mens Health, 2019 PubMed
-
Human case series reporting improved androgen levels and symptoms after pulsatile gonadorelin infusion by micropump.
Beijing Da Xue Xue Bao Yi Xue Ban, 2014 PubMed
-
Cochrane review of human trials of pulsatile GnRH for ovulation induction in polycystic ovary syndrome; evidence was limited.
Cochrane Database Syst Rev, 2004 PubMed
-
Review of side effects linked to fertility drugs, including debate over long-term cancer risk.
Drug Saf, 1994 PubMed
-
Human observational study linking the testosterone-to-estradiol ratio to erectile symptoms during recombinant hCG treatment.
Arch Endocrinol Metab, 2021 PubMed
-
Review of hypogonadism and undescended testes, noting low success rates of hormonal treatments such as hCG or GnRH.
Front Endocrinol (Lausanne), 2019 PubMed
-
Human observational study reporting that adding hCG to testosterone undecanoate did not change outcomes or side effects.
Asian J Androl, 2019 PubMed
-
Randomized human trial in men with hypogonadism reporting that clomiphene, hCG and their combination restored testosterone similarly.
BJU Int, 2018 PubMed
-
Randomized human study in late-onset hypogonadism comparing hCG with testosterone, reporting lower hematocrit and prostate measures with hCG.
Aging Male, 2016 PubMed
-
Human observational study comparing three hypogonadism treatments; hCG was associated with better testicular volume and lipid measures.
Clin Endocrinol (Oxf), 2013 PubMed
-
Human study in adolescent boys with Prader-Willi syndrome reporting that hCG for hypogonadism promoted puberty changes and normal muscle mass.
Horm Res, 2007 PubMed
-
Network meta-analysis of human IVF trials comparing ovarian stimulation protocols; several comparisons were underpowered.
Cochrane Database Syst Rev, 2025 PubMed
-
Human observational study in poor ovarian responders finding hp-hMG and recombinant FSH similarly effective.
Ceska Gynekol, 2024 PubMed
-
Assessor-blinded randomized human IVF trial reporting similar results for highly purified hMG and recombinant FSH in high responders.
Fertil Steril, 2020 PubMed
-
Systematic review of human IVF trials reporting more eggs retrieved per cycle with recombinant FSH than with urinary hMG.
J Endocrinol Invest, 2015 PubMed
-
Human IVF study describing pregnancy, miscarriage and ovarian hyperstimulation rates with an hMG-based protocol.
Hum Reprod, 2000 PubMed
-
Human study in hypogonadotropic adolescents reporting better puberty outcomes with hCG/hMG than with testosterone.
J Pediatr Endocrinol Metab, 1999 PubMed
-
Human observational study reporting that pulsatile GnRH and hCG/hMG were both effective in congenital hypogonadotropic hypogonadism.
Eur J Endocrinol, 1998 PubMed
-
Randomized human trial in men with severe oligospermia comparing hCG/hMG regimens; sperm measures were similar between groups.
J Clin Endocrinol Metab, 1987 PubMed
-
Randomized human study reporting that chronic kisspeptin-10 sustained gonadotropin and testosterone secretion in healthy men for 12 days.
Eur J Endocrinol, 2026 PubMed
-
Human study of continuous kisspeptin infusion in healthy men as a tool to study LH secretion.
Hormones (Athens), 2026 PubMed
-
Human study reporting that the reproductive axis in men remained responsive to kisspeptin-10 across the lifespan.
Andrologia, 2019 PubMed
-
Randomized human study in women on how neurokinin B and kisspeptin interact in estrogen feedback on reproductive hormones.
J Clin Endocrinol Metab, 2016 PubMed
-
Human study directly comparing intravenous kisspeptin-10, kisspeptin-54 and GnRH on reproductive-hormone release.
Hum Reprod, 2015 PubMed
-
Monkey study reporting that fasting suppressed the testosterone response to kisspeptin-10.
Horm Metab Res, 2014 PubMed
-
Human proof-of-concept study reporting that kisspeptin-10 raised LH pulse frequency and secretion in men with type 2 diabetes and low testosterone.
Clin Endocrinol (Oxf), 2013 PubMed
-
Human study reporting that the gonadotropin response to kisspeptin-10 varied with sex-steroid status in women.
Hum Reprod, 2012 PubMed
-
Human study reporting that kisspeptin-10 strongly stimulated LH secretion and increased LH pulse frequency in men.
J Clin Endocrinol Metab, 2011 PubMed
-
Monkey study proposing increased hypothalamic GPR54 (kisspeptin receptor) signaling as a trigger for puberty.
Proc Natl Acad Sci U S A, 2005 PubMed
-
Systematic review and meta-analysis of treatments for female sexual desire, arousal and orgasm disorders, including bremelanotide and flibanserin.
J Minim Invasive Gynecol, 2026 PubMed
-
Critical review arguing that bremelanotide's benefits for hypoactive sexual desire disorder were small and some outcomes post-hoc.
J Sex Res, 2024 PubMed
-
Phase 1 human data reporting that bremelanotide, via MC4R activation, reduced caloric intake and body weight in women with obesity.
Diabetes Obes Metab, 2022 PubMed
-
Analysis of safety across the bremelanotide clinical program, noting transient blood-pressure effects and caution in cardiovascular risk.
J Womens Health (Larchmt), 2022 PubMed
-
Review of bremelanotide's approval for hypoactive sexual desire disorder, including dosing limits and precautions.
Ann Pharmacother, 2020 PubMed
-
Two randomized phase 3 human trials reporting that bremelanotide (PT-141) improved sexual desire and reduced related distress in premenopausal women.
Obstet Gynecol, 2019 PubMed
-
Phase 2b dose-ranging human trial reporting that bremelanotide was well tolerated and improved efficacy measures versus placebo.
J Sex Med, 2019 PubMed
-
Early human study suggesting bremelanotide could improve subjective desire and arousal in premenopausal women with arousal disorder.
J Sex Med, 2006 PubMed
-
Meta-analysis of human trials reporting that aromatase inhibitors with ovarian suppression reduced breast cancer recurrence more than tamoxifen in premenopausal women.
Lancet Oncol, 2022 PubMed
-
Phase 3 human trial reporting that a 3-month triptorelin formulation was a valid alternative to a 1-month one for endometriosis in Chinese women.
Adv Ther, 2022 PubMed
-
Long-term human trial (PROMISE-GIM6) reporting reassuring safety of GnRH agonists during chemotherapy to preserve ovarian function.
J Natl Cancer Inst, 2022 PubMed
-
Randomized human trial reporting adverse body-composition and metabolic changes with GnRH agonists versus orchiectomy for androgen deprivation.
BJU Int, 2019 PubMed
-
Meta-analysis reporting that a 3-month triptorelin formulation suppressed hormones and slowed progression in children with central precocious puberty.
Horm Res Paediatr, 2017 PubMed
-
Randomized human trial (TEXT/SOFT) reporting that adjuvant exemestane plus ovarian suppression (including triptorelin) reduced recurrence in premenopausal breast cancer.
N Engl J Med, 2014 PubMed
-
Randomized human trial reporting that LHRH analogue treatment did not affect final height in girls with early puberty onset.
Arch Dis Child, 1999 PubMed
-
Human study using the GnRH agonist triptorelin as a diagnostic test for delayed puberty.
J Pediatr, 1995 PubMed
-
Cell study in which a vitamin C–linked AHK tripeptide was reported to enhance bone-forming differentiation of mouse myoblast cells.
Differentiation, 2018 PubMed
-
In cultured human hair follicles and cells, the copper peptide AHK-Cu was reported to promote hair growth and reduce cell-death signals.
Arch Pharm Res, 2007 PubMed
-
Review of acetyl hexapeptide-8 in cosmetics, noting low skin penetration as a limit on its effects.
Int J Mol Sci, 2025 PubMed
-
Expert panel safety review of acetyl hexapeptide-8 amide in cosmetics, concluding it is safe as used in those products.
Int J Toxicol, 2025 PubMed
-
Human study of a serum with argireline and hyaluronic acid; wrinkle and skin-age scores fell, but not significantly.
GMS Interdiscip Plast Reconstr Surg DGPW, 2023 PubMed
-
Human case report of a mycobacterial skin infection after an argireline injection into the face.
World J Clin Cases, 2021 PubMed
-
Randomized human study of two cosmetic peptides, reporting reduced wrinkle measures and lower water loss through skin with acetyl hexapeptide-3.
J Cosmet Dermatol, 2017 PubMed
-
Lab study using human and model skin that found acetyl hexapeptide-8 stayed mostly in the outer skin layers with little penetration.
Cutan Ocul Toxicol, 2015 PubMed
-
Small randomized human pilot in blepharospasm patients receiving botulinum toxin; topical acetyl hexapeptide-8 was reported to be safe.
Eur J Neurol, 2013 PubMed
-
Randomized human study in Chinese adults reporting a measurable reduction in wrinkle scores with topical argireline.
Am J Clin Dermatol, 2013 PubMed
-
Randomized human trial of a ready-to-use liquid botulinum toxin A (relabotulinumtoxinA), reporting reduced glabellar lines and a favorable safety profile.
Aesthet Surg J, 2024 PubMed
-
Network meta-analysis of human trials comparing botulinum toxin A products for glabellar lines, with daxibotulinumtoxinA ranking well on effect and tolerability.
Aesthetic Plast Surg, 2023 PubMed
-
Randomized human trial of glabellar botulinum toxin in borderline personality disorder; the authors describe the evidence as still limited.
J Psychopharmacol, 2022 PubMed
-
Systematic review of human data on complications from cosmetic botulinum toxin injections to the upper face; most reported events were mild and short-lived.
Aesthet Surg J, 2022 PubMed
-
Systematic review and meta-analysis of human trials reporting lower depression scores after glabellar onabotulinumtoxinA injections.
Plast Reconstr Surg, 2022 PubMed
-
Cochrane-style review of human trials of botulinum toxin type A for facial wrinkles, calling for longer-term comparative trials.
Cochrane Database Syst Rev, 2021 PubMed
-
Meta-analysis of randomized human trials reporting that a single botulinum toxin type A treatment reduced glabellar (frown) lines with good safety.
Plast Reconstr Surg, 2015 PubMed
-
Long-term human study reporting that repeated incobotulinumtoxinA treatment of frown lines remained effective and well tolerated for up to two years.
Dermatol Surg, 2013 PubMed
-
Systematic review of GHK-Cu research describing a large preclinical evidence base and a lack of well-designed human trials.
Arch Intern Med Res, 2026 PubMed
-
Review of GHK-Cu chemistry and formulation as a metallopeptide and drug-delivery cargo.
Pharmaceutics, 2026 PubMed
-
Preprint in middle-aged mice reporting better hippocampus-dependent learning after GHK-Cu given by injection or intranasally, through different pathways.
bioRxiv, 2026 Europe PMC
-
Mouse colitis study reporting that GHK-Cu reduced gut inflammation and Th17 cells via the SIRT1/STAT3 pathway.
Front Pharmacol, 2025 PubMed
-
Review of topical GHK and GHK-Cu as cosmetic peptides, covering skin permeability and formulation issues.
Bioimpacts, 2025 PubMed
-
Mouse and patient study linking lower GHK levels to muscle problems in COPD and reporting that GHK-Cu limited smoke-related muscle dysfunction in mice.
J Cachexia Sarcopenia Muscle, 2023 PubMed
-
Mouse and human lung-cell study reporting that GHK-Cu reduced cigarette smoke-induced emphysema, inflammation and oxidative stress.
Front Mol Biosci, 2022 PubMed
-
Human study of scalp injections of a multi-ingredient hair formulation including copper peptide, reporting increased hair regrowth.
J Cosmet Laser Ther, 2018 PubMed
-
Review proposing that GHK-Cu's reported effects relate to broad changes in gene expression seen in lab databases.
Int J Mol Sci, 2018 PubMed
-
Rat ligament-reconstruction study reporting that GHK-Cu injected into the joint briefly improved graft healing.
J Orthop Res, 2015 PubMed
-
Randomized human study after CO2 laser skin resurfacing finding no significant benefit from GHK-Cu skin-care products on recovery.
Arch Facial Plast Surg, 2006 PubMed
-
Human fibroblast study reporting that copper tripeptide affected growth and growth-factor production in normal and irradiated cells.
Arch Facial Plast Surg, 2005 PubMed
-
Fibroblast culture study reporting that GHK-Cu stimulated both production and remodeling enzymes of connective tissue.
Life Sci, 2000 PubMed
-
Meta-analysis of human cases supporting prompt hyaluronidase to treat blood-vessel complications from hyaluronic acid fillers.
Aesthetic Plast Surg, 2026 PubMed
-
Randomized human trial reporting that botulinum toxin plus hyaluronic acid filler reduced enlarged facial pores.
Toxins (Basel), 2025 PubMed
-
Meta-analysis of human trials reporting that oral hyaluronic acid supplements improved skin hydration, elasticity and wrinkle depth.
J Drugs Dermatol, 2025 PubMed
-
Systematic review and meta-analysis of human studies reporting that hyaluronic acid injections improved skin hydration and radiance.
J Cosmet Dermatol, 2025 PubMed
-
Systematic review of adverse events from hyaluronic acid facial fillers, generally mild and transient with rare serious events.
Aesthetic Plast Surg, 2024 PubMed
-
Randomized human trial reporting that a hyaluronic acid micro-filler improved superficial wrinkles and skin quality.
J Dermatolog Treat, 2023 PubMed
-
Systematic review and meta-analysis comparing monophasic and biphasic hyaluronic acid fillers for nasolabial folds, with comparable results.
J Cosmet Dermatol, 2022 PubMed
-
Meta-analysis of human trials reporting hyaluronic acid is an effective lip filler, with mostly mild to moderate side effects.
Front Surg, 2021 PubMed
-
Lab study of cationic pentapeptide lipopeptides reporting that peptide sequence influenced collagen-stimulating activity in cells.
J Pept Sci, 2026 PubMed
-
Lab study characterizing liposome-encapsulated palmitoyl-KTTKS and its collagen-stimulating effect in fibroblasts.
Pharmaceutics, 2024 PubMed
-
Rat burn-wound study reporting best healing when stem cells were combined with Pal-KTTKS-enriched cellulose dressings.
Arch Dermatol Res, 2024 PubMed
-
Randomized double-blind human trial reporting that a palmitoyl pentapeptide cream outperformed acetyl hexapeptide-3 and placebo for wrinkles.
J Clin Aesthet Dermatol, 2023 PubMed
-
Rat skin study comparing Matrixyl patch and cream, reporting signs of skin rejuvenation with both.
ACS Omega, 2022 PubMed
-
Lab study of new KTTKS analogs reporting none were toxic to fibroblasts and some promoted cell growth.
Molecules, 2019 PubMed
-
Cell study of palmitoyl-pentapeptide (Pal-KTTKS) and wound contraction, examining collagen and myofibroblast balance.
Tissue Eng Regen Med, 2017 PubMed
-
Human fibroblast study reporting that the peptide amphiphile C16-KTTKS stimulated collagen production.
Mol Pharm, 2013 PubMed
-
Randomized human trial reporting that topical palmitoyl pentapeptide (Matrixyl) reduced wrinkles and fine lines in photoaged facial skin.
Int J Cosmet Sci, 2005 PubMed
-
Human observational study reporting that cholecalciferol remained necessary for vitamin D deficiency in erythropoietic protoporphyria despite afamelanotide.
Br J Dermatol, 2024 PubMed
-
Open-label human proof-of-concept study reporting that afamelanotide was well tolerated in acute stroke patients, with apparent recovery.
BMC Neurol, 2023 PubMed
-
Review discussing afamelanotide as an orphan drug with potential uses across several skin conditions.
J Drugs Dermatol, 2021 PubMed
-
Review of afamelanotide (Melanotan I) research in erythropoietic protoporphyria, summarizing efficacy and safety from phase III trials.
Am J Clin Dermatol, 2016 PubMed
-
Review of unwanted pigmentation that warns against unregulated products such as Melanotan I and mercury-containing bleaching creams.
Hautarzt, 2015 PubMed
-
Randomized multicenter human trial reporting faster, greater repigmentation in vitiligo with afamelanotide implants plus narrowband UV-B.
JAMA Dermatol, 2015 PubMed
-
Randomized human trial reporting that afamelanotide (Melanotan I) increased pain-free sun exposure in erythropoietic protoporphyria.
N Engl J Med, 2015 PubMed
-
Human case report describing persistent gum pigmentation after Melanotan II injections.
Life (Basel), 2026 PubMed
-
Human case report discussing whether Melanotan II nasal spray could be linked to oral mucosal melanoma.
Int J Oral Maxillofac Surg, 2025 PubMed
-
Rat chronic-stress study reporting antidepressant-like and anti-stress effects of the ACTH(4-10) analogs Semax and Melanotan II.
Eur J Pharmacol, 2024 PubMed
-
Human case report cautioning about side effects of self-administered Melanotan II ("the Barbie drug").
Ned Tijdschr Geneeskd, 2022 PubMed
-
Human case report and literature review of possible kidney infarction associated with Melanotan II.
CEN Case Rep, 2020 PubMed
-
Human case report of priapism (prolonged erection) linked to melanocortin analog (melanotan) use.
BMJ Case Rep, 2019 PubMed
-
Review of the risks of unregulated alpha-MSH analog (melanotan) use.
Int J Dermatol, 2017 PubMed
-
Human case report of melanoma arising in a Melanotan II user, highlighting potential risks.
Dermatology, 2014 PubMed
-
Human case report of systemic toxicity and rhabdomyolysis after Melanotan II injection.
Clin Toxicol (Phila), 2012 PubMed
-
Human studies of melanocortin agonists reporting effects of Melanotan II-type compounds on penile erection and sexual motivation.
Int J Impot Res, 2000 PubMed
-
Pilot phase I human study reporting that Melanotan II produced tanning after a few low subcutaneous doses.
Life Sci, 1996 PubMed
-
Review of hair-regrowth approaches centered on Wnt/beta-catenin signaling, including peptides such as PTD-DBM.
Cells, 2025 PubMed
-
Mouse study reporting that an adhesive hydrogel patch delivering PTD-DBM and valproic acid promoted regenerative wound healing.
Adv Healthc Mater, 2023 PubMed
-
Mouse study reporting that CXXC5 mediates DHT-driven hair loss via PGD2, and that inhibiting it eased hair loss.
Cells, 2023 PubMed
-
Mouse study reporting that a CXXC5-blocking peptide (PTD-DBM) activated Wnt/beta-catenin signaling and accelerated hair regrowth.
J Invest Dermatol, 2017 PubMed
-
Rodent cell study reporting that blocking the Dishevelled-CXXC5 interaction activated Wnt/beta-catenin signaling and bone-cell differentiation.
Cell Death Differ, 2015 PubMed
-
Mouse wound study reporting that PTD-DBM with a GSK3 inhibitor activated Wnt/beta-catenin signaling and improved skin wound healing.
J Exp Med, 2015 PubMed
-
Human study of a dissolving microneedle patch (including SNAP-8-type peptides) reporting anti-wrinkle effects without skin safety concerns.
Ann Dermatol, 2024 PubMed
-
Human clinical study of bioactive-peptide microneedle patches reporting multi-targeted improvements in skin aging.
J Cosmet Dermatol, 2020 PubMed
-
Review of peptides in facial plastic surgery and aesthetics, covering their roles, safety and efficacy.
Facial Plast Surg, 2026 PubMed
-
Human study of a serum with acetyl hexapeptide-8 and Syn-Ake-type peptides reporting improvements in wrinkles and skin quality.
Int J Cosmet Sci, 2026 PubMed
-
Lab and computer-modeling study reporting anti-aging activity for the Syn-Ake peptide.
J Biomol Struct Dyn, 2024 PubMed
-
Lab study assessing anticancer activity of venom-derived and biomimetic neurotoxin peptides (including Vialox-type) in cancer cell lines.
Cell Biochem Biophys, 2026 PubMed
-
Lab and computer-modeling study evaluating the Vialox and Leuphasyl pentapeptides for anti-aging activity.
Chem Biodivers, 2026 PubMed
-
Rat focal-stroke study reporting better recovery on a motor coordination test after intranasal DSIP.
Molecules, 2021 PubMed
-
Rat study simulating high-altitude sleep loss reporting that phosphorylated DSIP restored spatial memory and related brain signaling.
Life Sci, 2018 PubMed
-
Randomized human study during anesthesia reporting that DSIP lightened measured anesthetic depth and altered heart-rate variability.
Eur J Anaesthesiol, 2009 PubMed
-
Review describing DSIP as still poorly understood, with no confirmed receptor or gene despite decades of research.
J Neurochem, 2006 PubMed
-
Double-blind human trial in chronic insomnia; DSIP effects on sleep were weak and partly explained by placebo-group changes.
Neuropsychobiology, 1992 PubMed
-
Human study in severe chronic insomnia reporting changes in 24-hour sleep-wake patterns and daytime alertness during DSIP treatment.
Eur Neurol, 1987 PubMed
-
Human study of short-term DSIP in poor sleepers; apparent differences from placebo were already present at baseline.
Int J Clin Pharmacol Res, 1987 PubMed
-
Small human study in chronic pain patients reporting lower pain scores in six of seven during a DSIP series.
Eur Neurol, 1984 PubMed
-
Human study of synthetic DSIP in disturbed sleep, reporting sleep-promoting effects only in the second hour after injection.
Experientia, 1981 PubMed
-
Systematic review and meta-regression of human trials examining how melatonin timing and amount related to sleep outcomes.
J Pineal Res, 2024 PubMed
-
Meta-analysis reporting that prolonged-release melatonin and ramelteon were effective versus placebo for insomnia symptoms.
J Sleep Res, 2023 PubMed
-
Network meta-analysis comparing drugs for insomnia, including melatonin, on efficacy and adverse effects.
Lancet, 2022 PubMed
-
Systematic review and meta-analysis reporting melatonin was not clearly effective for chronic insomnia in adults but might help children and adolescents.
Sleep Med Rev, 2022 PubMed
-
Systematic review and meta-analysis reporting a generally good safety profile for higher melatonin doses in adults, with limited data.
J Pineal Res, 2022 PubMed
-
Systematic review of medications for sleep disturbance in dementia, noting some benefit from trazodone and orexin antagonists.
Cochrane Database Syst Rev, 2020 PubMed
-
Cochrane-style review concluding that oral melatonin probably reduces jet-lag symptoms.
Medwave, 2015 PubMed
-
Meta-analysis of human trials reporting that melatonin shortened time to fall asleep, increased sleep time and improved sleep quality.
PLoS One, 2013 PubMed
-
Randomized placebo-controlled human trial finding that intranasal oxytocin four times daily for 8 weeks did not reduce body weight in adults with obesity.
NEJM Evid, 2024 PubMed
-
Randomized human trial suggesting intranasal oxytocin as an add-on might improve outcomes in severely ill psychiatric inpatients, pending more research.
Neuropsychobiology, 2023 PubMed
-
Systematic review finding that intranasal oxytocin did not significantly affect overeating or weight in Prader-Willi syndrome.
Diabetes Metab Syndr, 2023 PubMed
-
Randomized human trial finding intranasal oxytocin ineffective for core autism symptoms in children with Phelan-McDermid syndrome.
Mol Autism, 2021 PubMed
-
Systematic review and meta-analysis finding no consistent benefit of intranasal oxytocin for schizophrenia symptoms.
Int J Neuropsychopharmacol, 2021 PubMed
-
Placebo-controlled randomized human trial finding no significant benefit of intranasal oxytocin for social function in children and adolescents with autism.
N Engl J Med, 2021 PubMed
-
Meta-analysis of intranasal oxytocin and social cognition in neurodevelopmental disorders, calling for better-designed trials.
Psychoneuroendocrinology, 2018 PubMed
-
Systematic review of randomized human trials of oxytocin in autism, noting possible effects on emotion recognition and eye gaze.
J Child Adolesc Psychopharmacol, 2014 PubMed
-
Meta-analysis reporting that sublingual and oral vitamin B12 were as effective as intramuscular injections for improving B12 status.
Front Pharmacol, 2025 PubMed
-
Systematic review reporting that vitamin B12 helps clinical deficiency but offers limited neurological benefit in subclinical cases.
Cureus, 2025 PubMed
-
Meta-analysis reporting that intramuscular, oral and sublingual vitamin B12 all effectively raised B12 levels without major differences.
Ir J Med Sci, 2024 PubMed
-
Randomized crossover human trial examining vitamin B12 injections for mild voice symptoms in professional singers.
JAMA Otolaryngol Head Neck Surg, 2021 PubMed
-
Cochrane review comparing oral and intramuscular vitamin B12 for deficiency, calling for better-designed trials.
Cochrane Database Syst Rev, 2018 PubMed
-
Human study reporting improved cognitive and electrographic brain measures after cobalamin supplementation in older, deficient people.
J Gerontol A Biol Sci Med Sci, 2001 PubMed
-
Randomized human trial reporting that oral cobalamin effectively treated vitamin B12 deficiency, with favorable markers versus injection.
Blood, 1998 PubMed
-
Randomized human trial comparing a liver extract-folic acid-B12 preparation with placebo for chronic fatigue syndrome, finding no significant difference.
Arch Intern Med, 1989 PubMed
-
Dermatology review naming benzyl alcohol a notable contact allergen and noting it is often missed in standard patch testing.
Dermatitis, 2026 PubMed
-
Review of human studies using benzyl-alcohol-preserved saline to reduce discomfort from injections around the eye.
Eye (Lond), 2022 PubMed
-
Randomized human study finding no significant pain differences between bacteriostatic saline and buffered lidocaine before IV placement.
J Perianesth Nurs, 2012 PubMed
-
Lab study on human retinal pigment cells reporting that benzyl alcohol, used as a drug vehicle, can be toxic to these cells.
Exp Eye Res, 2008 PubMed
-
Human study comparing intradermal bacteriostatic saline with other pretreatments; reported IV-insertion pain did not differ significantly.
AANA J, 1998 PubMed
-
Randomized trial in children comparing saline with benzyl alcohol and lidocaine as skin anesthetics before IV placement; both performed similarly.
Pediatr Emerg Care, 1998 PubMed
-
Human study in newborns describing how benzyl alcohol is metabolized and cleared, and the limits of their capacity to do so.
Dev Pharmacol Ther, 1988 PubMed
-
Lab report describing a chemical incompatibility between the drug ifosfamide and benzyl-alcohol-preserved bacteriostatic water.
Am J Hosp Pharm, 1988 PubMed
-
Human case report describing "gasping syndrome" in newborns linked to benzyl alcohol, the preservative in bacteriostatic water.
N Engl J Med, 1982 PubMed
-
Human case report of water intoxication after intravenous infusion of sterile water, highlighting it as a preventable harm.
Cureus, 2025 PubMed
-
Human harm-reduction study of alternative injection-preparation fluids among people who inject drugs, underscoring the need for sterile water.
Harm Reduct J, 2020 PubMed
-
Review of intravenous sterile water to lower blood sodium in high-sodium states when enteral routes are unavailable.
Anaesth Intensive Care, 2014 PubMed
-
Lab study evaluating osmolality and pH of chemotherapy drugs diluted for injection, relevant to sterile diluents.
J Oncol Pharm Pract, 2009 PubMed
-
Human report of an Australia-wide bloodstream-infection outbreak traced to contaminated "sterile" water ampoules.
Med J Aust, 1990 PubMed
-
Human case series describing intravenous sterile water via central catheter to treat hyperosmolar coma.
Arch Intern Med, 1986 PubMed
-
Rat bone-cell study reporting that myostatin increased production of the hormone FGF23.
Pflugers Arch, 2021 PubMed
-
Mouse muscle-cell (C2C12) study finding that myostatin signaling effects weakened sharply once the cells matured.
Biomolecules, 2020 PubMed
-
Mouse study of artery re-narrowing reporting that myostatin limited smooth-muscle cell growth but not local inflammation.
Int J Mol Sci, 2020 PubMed
-
Mouse myoblast study reporting that myostatin increased, rather than reduced, cell proliferation, questioning this cell model.
Endocrinology, 2014 PubMed
-
Mouse muscle-injury study reporting that added myostatin increased fibrous scar tissue in a dose-related way.
J Histochem Cytochem, 2012 PubMed
-
Mouse study reporting that raising myostatin levels throughout the body caused marked muscle and fat loss resembling cachexia.
Science, 2002 PubMed
No papers match that search or filter.
For research use only. Not for human consumption. Summaries describe published findings and are not medical advice.
Reported finding
About this study
Study at a glance
Reading this type of study
Summary and notes written in-house from the published record, describing reported findings only. For research use only. Not medical advice.
